

**CURRICULUM VITAE**

(Updated on 14 Jan 2017)

**PROF CHNG WEE JOO****MB ChB, PhD, FRCP (Edin), FRCPath (UK), FAMS  
(Haematology)****Address:**National University Hospital  
National University Cancer Institute Singapore  
NUHS Tower Block, Level 7, Singapore 119228**PERSONAL INFORMATION**

<b>Place of Birth:</b>	<b>Singapore</b>
<b>Date of Birth:</b>	<b>March 20, 1971</b>
<b>Nationality:</b>	<b>Singaporean</b>
<b>Marital Status:</b>	<b>Married</b>
<b>Army:</b>	<b>Enlisted 1990, Completed 2011, highest rank 3SG</b>

**PROFESSIONAL QUALIFICATIONS**

**PhD (National University of Singapore) - 2011**  
**FELLOWSHIP OF THE ROYAL COLLEGE OF PHYSICIAN (Edinburgh) - 2011**  
**FELLOW, ACADEMY OF MEDICINE, SINGAPORE - 2008**  
**FELLOWSHIP OF THE ROYAL COLLEGE OF PATHOLOGIST (UK) – March 2005**  
**SPECIALIST ACCREDITATION IN HAEMATOLOGY (Singapore) – August 2004**  
**DIPLOMA ROYAL COLLEGE OF PATHOLOGIST (UK) – July 2004**  
**MEMBERSHIP OF THE ROYAL COLLEGE OF PHYSICIANS (UK) - July 2000**  
**MB ChB (University of Leeds) – 1997**

**PROFESSIONAL APPOINTMENTS****Current Appointment****DIRECTOR – NATIONAL UNIVERSITY CANCER INSTITUTE, SINGAPORE**

National University Health System, Singapore (01-09-14 to current)

**HEAD – DIVISION OF CLINICAL HAEMATOLOGY**

National University Health System, Singapore (01-01-13 to current)

**SENIOR CONSULTANT – HAEMATOLOGY**

National University Hospital, Singapore (01-01-12 to Current)

**LEAD – HAEMATOLOGICAL MALIGNANCY**

National University Cancer Institute of Singapore, NUHS (01-07-08 to current)

**DEPUTY DIRECTOR**

Cancer Science Institute, Singapore, National University of Singapore (01-08-12 to current)

**SENIOR PRINCIPAL INVESTIGATOR**

Cancer Science Institute, Singapore, National University of Singapore (01-10-08 to current)

**PROFESSOR – MEDICINE**

Yong Loo Lin School of Medicine, National University of Singapore (01-07-15 to current)

**Concurrent External Appointment****CHAIRMAN – NMRC Cancer Research Taskforce (June 2016 – current)**

**MEMBER – AMERICAN SOCIETY OF HAEMATOLOGY SCIENTIFIC COMMITTEE ON PLASMA CELL NEOPLASIA** (Jan 2014 to Current)

**FACULTY MEMBER – FACULTY 1000**

Lymphoma and Myeloma (April 2013 -)

**ADJUNCT PRINCIPAL INVESTIGATOR**

Institute of Molecular And Cell Biology, Singapore (Dec 2011 To Current)

**MEMBER – CSI GRADUATE STUDIES COMMITTEE**

Cancer Science Institute, Singapore, National University of Singapore (01-01-13 to current)

**PRESIDENT – SINGAPORE SOCIETY OF HAEMATOLOGY** (2015-)

**VISITING CONSULTANT – HAEMATOLOGY**

Singapore Armed Forces (Jan 2013 – Dec 2015)

**EDITORIAL BOARD MEMBER**

Asia-Pacific Journal of Oncology and Hematology (2009-)

Centrosome Research (2011-)

Blood Research (2016-)

**BOARD MEMBER**

Chapter of Haematologist, Academy of Medicine, Singapore (2009 to current)

**MEMBER**

MOH Drug Advisory Committee Oncology Drug Subcommittee (2015-)

**MEMBER**

National Medical Research Council New Investigator Award Local Review Panel (2012 to current)

**MEMBER – NUHS RESEARCH AWARDS COMMITTEE**

National University Health System (2011-)

**MEMBER – ASSOCIATE PROFESSORIAL FACULTY PROMOTION AND TENURE COMMITTEE**

National University of Singapore (2011-)

**MEMBER – TISSUE REPOSITORY OVERSIGHT COMMITTEE**

National University Health System (2011-)

**MEMBER – NUHS CLINICIAN-RESEARCHERS MENTORSHIP COMMITTEE**

National University Health System (2011 -)

**MEMBER – SCHOOL GRADUATE PROGRAM COMMITTEE**

National University of Singapore (2011 -)

**MEMBER – INTERNATIONAL MYELOMA WORKING GROUP** (2010 onwards)

**MEMBER – ASIAN MYELOMA NETWORK** (2011 onwards)

**MEMBER – ASIAN LYMPHOMA STUDY GROUP** (2010 onwards)

### Previous Appointments

**CHAIRMAN - NHG DOMAIN B2 DSRB** (2011-2016)

**MEMBER – RESEARCH ETHICS COMMITTEE**

National Healthcare Group (2011 to 2016)

**CHAIRMAN – CSI GRADUATE STUDIES COMMITTEE**

Cancer Science Institute, Singapore, National University of Singapore (01-01-13 to 30-06-2016)

**ASSOCIATE PROFESSOR – MEDICINE**

Yong Loo Lin School of Medicine, National University of Singapore (01-11-07 to 30-06-2015)

**VICE PRESIDENT – SINGAPORE SOCIETY OF HAEMATOLOGY** (2013-2014)

**ASSOCIATE DIRECTOR (RESEARCH)**

National University Cancer Institute of Singapore, NUHS (01-10-12 to 30-08-14)

**NHG DOMAIN B DSRB**

Deputy Chairman (2008-2010)

**EDITORIAL BOARD MEMBER**

Singapore Medical Journal (2008-2011)

Annals of the Academy of Medicine Singapore (2012-2013)

**MEMBER – FACULTY RESEARCH COMMITTEE**

National University of Singapore (2010-2014)

**MEMBER - NUHS RESEARCH TASK FORCE**

National University Health System (2009 to 2014)

**MEMBER – GRADUATE CURRICULUM REVAMP COMMITTEE**

National University of Singapore (2010)

**MEMBER – CSI GRADUATE STUDIES COMMITTEE**

Cancer Science Institute, Singapore, National University of Singapore (01-07-09 to 31-12-2012)

**CONSULTANT – HAEMATOLOGY**

National University Hospital, Singapore (01-01-07 to 31-12-2011)

**VISITING SCIENTIST – MULTIPLE MYELOMA GENOMICS**

Hematological Malignancies Lab (PI – Rafael Fonseca), Johnson Research Building, Mayo Clinic Scottsdale (11-10-04 to 5-10-07)

**ASSOCIATE CONSULTANT – HAEMATOLOGY**

National University Hospital, Singapore (01-09-04 to 31-12-06)

**RESEARCH LABORATORY ATTACHMENT – CEBPA mutation in AML (Dr Motomi Osato)**  
RUNX Lab (PI – Prof Yoshiaki Ito), Institute of Molecular and Cell Biology, Biopolis, Singapore (01-05-04 to 31-08-04)

**REGISTRAR – HAEMATOLOGY**

National University Hospital, Singapore (01-08-01 to 31-08-04)

**MEDICAL OFFICER (SPECIALIST) – HAEMATOLOGY-ONCOLOGY**

National University Hospital, Singapore (14-02-01 to 31-07-01)

**SENIOR HOUSE OFFICER – HAEMATOLOGICAL ONCOLOGY**

Christie Hospital, Manchester, UK (03-08-00 to 01-02-01)

**SENIOR HOUSE OFFICER – INTERNAL MEDICINE**

York District Hospital, York, UK (01-08-98 to 01-08-00)

**PRE-REGISTRATION HOUSE OFFICER – MEDICINE**

Leeds General Infirmary, Leeds, UK (01-02-98 to 31-07-98)

**PRE-REGISTRATION HOUSE OFFICER – SURGERY**

St James University Hospital, Leeds, UK (01-08-97 to 31-01-98)

**PRIZES AND AWARDS**

**Post-Graduate**

2016	26 <sup>th</sup> Seah Cheng Siang Memorial Lecture
2016	NMEA National Outstanding Clinician-Scientist Award
2016	NUHS Academic Medicine Development Award
2013	SMJ Best Reviewer 2012
2012	NMRC Clinician Scientist (Senior) Award
2011	Chua Hua Toh Memorial Gold Medal (Best Graduate Thesis in Life Science)
2011	NUS Young Researcher Award
2010	YLL SOM Faculty Outstanding Researcher Award (Young Researcher Category)
2009	JCI The Outstanding Young Persons (TOYP) Award
2008	NHG Investigator Clinician Scheme Award
2008	NMRC Clinician Scientist (INV) Award
2007	Celgene Future Leaders in Haematology Award
2007	SMJ Best Reviewer Award 2006
2006-2007	Multiple Myeloma Research Foundation Fellowship
2006	Singapore Medical Journal Best Research Paper 2005 (Second Prize)
2005	Best Oral Presentation Arizona Academic Excellence Day
2004-2006	A*Star International Fellowship
2004	Singapore Society of Haematology Annual Scientific Meeting Best Oral Presentation
2003	Courage Star
2002	Singapore Society of Haematology Annual Scientific Meeting Best Oral Presentation

**Medical Education**

1997	John Ingram Prize in Dermatology
1997	Garland Prize in Clinical Neurology
1996	Dora Radcliff Elective Travel Award
1996	Thorp Award (Elective Project and Research Award)
1994	Infirmary Prize (Best Overall Result in Second Year)
1994	Newman Prize in Physiology
1993	Crabtree Prize (Good Performance in First Year)
1992 - 1996	Tetley and Lupton Scholarship (from University of Leeds)

**Secondary Education**

1988	Ministry of Education Scholarship
------	-----------------------------------

**PROFESSIONAL MEMBERSHIP**

Singapore Medical Association  
Royal College of Physician of Edinburgh  
Royal College of Pathologist  
Singapore Society of Haematology  
American Society of Hematology (Member ID 1004375)  
American Association of Cancer Research (Membership No. 127996)

**PROFESSIONAL SERVICES**

**Peer Review for:**

Blood [Review more than 10 manuscript per year for each of the last 5 years]  
 PNAS  
 Cancer Research  
 Leukaemia  
 Oncogene  
 Haematologica/Haematology Journal  
 British Journal of Haematology  
 PlosONE  
 Molecular Cancer  
 Experimental Hematology  
 Leukemia and Lymphoma  
 Haemostasis and Thrombosis  
 Proteomics  
 Journal of Clinical Pathology  
 Cancer Therapy  
 Antioxidants and Redox Signalling  
 International Journal of Biochemistry and Cell Biology  
 Journal of Leukocyte Biology  
 International Journal of Molecular Science  
 Asian Journal of Haematology-Oncology  
 Singapore Medical Journal  
 Annals of the Academy of Medicine Singapore  
 Critical Reviews in Oncology/Hematology

**Grant Review for:**

Multiple Myeloma Research Foundation  
 Medical Research Council of South Africa  
 National Medical Research Council, Singapore  
 National University of Singapore

**Judging Panel for:**

WSPC-ICAAS Most Outstanding JC Science Student Award and SIYSS (2008-2013)

**Conference Organising Committee**

Member, Scientific Committee, NHG Annual Scientific Meeting (2008-2009)  
**Chairman**, Scientific Committee, 1<sup>st</sup> Singapore Health and Biomedical Congress (2010)  
**Organizing Co-Chair**, The International Hematology Malignancy Conference 'Bridging The Gap' (2010-2011)  
**Co-Chair**, Scientific Committee, Asian Federation of Haematology Meeting 2012  
 Member, Scientific Committee, Mitochondria, Apoptosis and Cancer 2011  
**Organizing Co-Chair**, Highlights of ASH Asia 2012 and 2014  
**Scientific Co-Chair**, ASEAN Federation of Haematology Congress 2012  
**Chair Organizing Committee**, Asia-Pacific Bone Marrow Transplant Meeting 2016  
 Member, Scientific Committee, International Myeloma Workshop 2017

**Advisory Boards**

Celgene CpGEMM (Epigenetics in Myeloma) Think Tank  
 Onyx PRISM NTP (Proteosome Research and Integrative Science for Multiple Myeloma – Novel Therapies Program) – Molecular Profiling Working Group

**Steering Committee For Global Clinical Trials**

1) Member, Global Phase III trial of MLN9708 versus placebo for maintenance therapy in newly diagnosed myeloma after autologous stem cell transplant.  
 2) Member, Global Phase III trial of MLN9708 versus placebo for maintenance therapy in newly diagnosed myeloma who are not eligible autologous stem cell transplant.

**TEACHING****Teaching – Medical Students**

- 1) M1 Lecture – Haematopoietic System: Clinical Applications (from 2011)
- 2) M2 Phase II lecture – Causes of Cancer (From 2011)
- 3) M3 ambulatory teaching (From 2010)
- 4) M3 Lecture – Approach to Cytopenias (From 2009)

- 5) CFSC Tutor (2008)
- 6) Combine teaching session – Principles of Cancer Therapy (AY 2009/2010, and AY 2011/2012)
- 7) Combine teaching session – Abnormal Laboratory Results (AY 2010/2011)
- 8) M5 Acute Medicine Lecture – Haematological Emergencies

#### Teaching – Postgraduate

- 9) Master of Clinical Investigation Lecture: Biomarkers in Clinical Trials (2009 Onwards)
- 10) CDM5101 – Fundamentals of Cancer: Receptor Tyrosine Kinase (AY2011 onwards)
- 11) MDG5218: Biochemical and Genetic Approaches to Understanding Cell Biology. Genetics of Hairy Cell leukaemia. (2011 onwards)
- 12) GS6882A – Biology of Disease: Haematologic Malignancies

#### Teaching – Others

- 13) 3<sup>rd</sup> BDS lecture – Approach to Anaemia

#### Mentoring / Supervision

- 1) Thesis Advisory Committee
  - a. Anthony Sagarayaj (Dan Yock Young's student, A0051455, SOM RS)
  - b. Meng Xuan (Chairman, Phil Koeffler's student, A0075546X, CSI)
  - c. Cheryl Leong Kit Mun (Chang Young Tae's student, A0078244B, NGS)
  - d. Liu Yilin (Fu Xinyuan's Student, A00238230, NGS)
  - e. Kwok Hui Si (Dan Tenen's Student, A0091937U, NGS)
  - f. Desmond Chin Wai Loo, 2011-current (Motomi Osato's student, A0081608E, CSI)
  - g. Grace Koh Shimin, 2013-current (Chairman, Allen Yeoh's Student, SOM)
  - h. Chen Ye, 2011-Current (Chairman, Phil Koeffler's Student, CSI)
  - i. Masturah Bte Mohd Abdul Rashid (Member, Ed Chow's Student, CSI)
  - j. Gokce Oguz (Chairman, Yu Qiang's Student, Physiology, SOM)
  - k. Mohammad Sufyan (Member, Chang Chan Fong's Student, Biochemistry, SOM)
  - l. Winnie Choo (Member, Ding Jeak Ling's Student, Faculty of Science, NUS)
  - m. Lim Yew Suang, Joshua (Member, Allen Yeoh's Student, YLLSOM, NUS)
  - n. Jean Leong Kim Bee (Member, Sudhakar Jha's student, CSI)
  - o. Han Lin (Chairman, Phil Koeffler's student, SOM)
  - p. Muhammad Sufyan Bin Masroni (Chairman, Chang Chan Fong's student, SOM)
  - q. Zeng Qun (Member, Herbert Schwarz's Student, SOM)
  - r. Zhang Xi Yun (Member, SOM)
- 2) Honors Student
  - a. Ching Ying Qing, 2013-14
  - b. Fong Wen Xuan, 2014-15
  - c. Ng Boon Yee, 2015-2016
  - d. Hee Yan Ting, 2015-2016
  - e. Wu Zhengwei, 2015-2016
  - f. Muhamad Irfan Bin Azaman, 2015-2016
- 3) Graduate Student
  - a. Dawn Nin Sijin (Dept of Medicine, NUS), 2007-2012 "Role of Misfolded-Nuclear receptor co-repressor N-CoR) induced transcriptional de-regulation in the pathogenesis of acute monocytic leukemia (AML-M5)" [Post-doc Deng Lih Wen]
  - b. Koh Tze Loong, MSc (Dept of Medicine, NUS), 2010-2012. "Functional Relevance and Downstream Pathways of EZH2 in Nasal-type Natural Killer / T-cell Lymphoma (NKTL)" [Industry]
  - c. Norlizan Binte Abdol Malek (SOM, NUS), 2009-2013 (Co-supervisor with Prakash Hande). "Regulation of TGF-beta signalling by Nuclear Receptor Co-Repressor (N-CoR) in Gastric Cancer Cells"
  - d. Phyllis Chong Shu Yun, PhD (CSI, NUS), 2010-2014. "Global Discovery of Dysregulated Protein Expression and Phosphorylation Networks Identified LEO1 as a Key Substrate of PRL-3 Phosphatase in Leukemogenesis" [Post-doc CSI CWJ]
  - e. Teoh Phaik Ju, PhD (Dept of Medicine, NUS), 2010-2014. "Genomic and Functional Characterization of the p53 Pathway in Relation to 17p13 (Del) in Multiple Myeloma (MM) and its Implications on Novel p53-Reactivating Therapies" [Post-doc CSI CWJ]
  - f. Kong Li Ren, PhD (Dept of Pharmacology, NUS), 2009-2014 (Co-supervisor with Goh Boon Cher). "Overriding Cisplatin Resistance in Lung Squamous Cell Carcinoma: Insights from Combination with HDAC Inhibitor" [Post-doc CSI GBC]

- g. Kelly Ong Ooi Kee, PhD (CSI, NUS), 2010-2014. “Role of Notch and JAK-STAT signalling pathways in acute megakaryoblastic leukemia” [Post-doc CSI MO]
  - h. Koh Cai Ping (CSI, NUS), 2010-2014. “The Generation of RUNX1 enhancer, ER1-Cre ERT2 Transgenic Mouse for Haematopoietic Stem Cell Specific Marking, Gene Targeting and Transgenesis” (Co-supervisor with Motomi Osato)
  - i. Viknesvaren Selvarajan, PhD (Dept of Medicine, NUS), 2011-2016. “Characterization of the Biological and Clinical Relevance of RUNX3 gene in Natural Killer / T-cell Lymphoma” [Post-doc Ng Siok Bian, NUS Pathology]
  - j. Bi Chonglei, PhD (Dept of Medicine, NUS), 2010-2015. “Genome-wide pharmacologic unmasking identifies tumor suppressor microRNAs in multiple myeloma” [Industry - BGI]
  - k. Sylvia Mahara, PhD (CSI, NUS), 2011-2015. “EZH2 and FOXM1 Crosstalk in Triple Negative Breast Cancer” [Post-doc Melbourne Australia]
  - l. Lu Xiao (CSI, NUS), 2011-2016. “Elucidation of the role of XIAP In modulating cell death signaling pathways In acute myeloid leukemia”
  - m. Zhou Yafeng (CSI, NUS), 2011-2016 (Co-supervisor with Phil Koeffler). “Targeting the Epigenetic Mechanism in Acute Myeloid Leukemia” [BGI]
  - n. Tan Ming (CSI, NUS), 2012 – 2017 (Co-supervisor Ruby Huang). “Establishing an Epithelial Mesenchymal Transition (EMT) Spectrum with EMT Transcriptional Drivers”
  - o. Li Boheng (SOM, NUS) 2013 – Current
  - p. Chooi Jing Yuan (SOM, NUS) 2014 – Current
  - q. Lee Kwok Kin (CSI, NUS, 2015 – Current (Co-supervisor Sudhakar Jha)
  - r. Liu Yanjing (SOM, NUS) 2015- Current (Co-Supervisor Dan Tenen)
  - s. Zhang Chujing (SOM, NUS) 2015 – Current (Co-Supervisor with Takaomi Sanda)
  - t. Zhang Xiyun (SOM, NUS) 2015 – Current (Co-Supervisor with Edward Chow)
- 1) Supervisor for Clinician Scientist
    - a. Ben Yan (Exxon-Mobil Fellowship)
    - b. Ng Chin Hin (MCI, NMRC Research Fellowship)
    - c. Loius Chai (CSA Junior)
    - d. Daniel Chan (NMRC CS-NIG Nov 2011 – “Elucidating the role of Phosphodiesterase 4D (PDE4D) inhibitors in cancer”)
    - e. Dr Zhou Jianbiao (NMRC CS-NIG Nov 2011 - Understanding Role and Molecular Mechanism of LIN28B-Let-7 microRNA Regulatory Axis in Leukemia Stem Cell)
    - f. Lawrence Lee (Academic Mentoring Scheme)
  - 2) Supervisor for Nurse Clinician (Lim Chi Ching)

### Examination Committee / Invigilation

- 1) Member of final MBBS MCQ committee (2008-)
- 2) Clinical coordinator for 3<sup>rd</sup> profession BDS examine (2008)
- 3) Final MBBS Re-examination 2007/2008 – Marker for OSCE.
- 4) M3 Examiner (2008-)
- 5) Final MBBS exam – Long and short case (2008-)
- 6) PQE Examiner
  - a. Wang Tingting (2012)
  - b. Meng Xuan (2013)
  - c. Ng Hong Kiat (2013)
  - d. Yang Fan (2013)
  - e. Kok Hui Si (2013)
  - f. Chong Qing Yun (2014)
  - g. Xiao Jinfen (2014)
  - h. Joshua Lim Yew Suang (2014)
  - i. Muhammad Sufyan Bin Masroni (2015)
  - j. Ding Ning (2016)
  - k. Sultan Abda Neja (2016)
- 7) Thesis examination
  - a. Tan Lee Hwie (Richie’s Student; MSc, 2009)
  - b. Jiang Nan (Allen,s Student; PhD, 2010)
  - c. Chelsia Wang Qiuxia (Motomi’s Student; PhD, 2011)
  - d. Wong Mei Mei Sharon (Jay Lu’s Student; PhD, 2012)
  - e. Lee Shuet Theng (Yu Qiang’s student; PhD, 2012)
  - f. Seah Bee Kee Serena (Shazib’s student; PhD, 2012)
  - g. Liu Yilin (Prof Fu’s Student, PhD, 2013)
  - h. Shriram Venkatesan (Prakash’s Student; PhD, 2013)
  - i. Fhu Chee Wai (Yaw Chyn’s student; PhD, 2013)
  - j. Zahra Kabri (David Virschup’s Student; PhD 2014)
  - k. Chong Mei Ling (Richie Soong’s Student; PhD 2014)

- l. Cheryl Leong (Chang Young-Tae's Student; PhD 2014)
- m. Jaymie Lin SiQi (Dan Yock Young's Student; PhD 2014)
- n. Tay Lavina Sierra (Yoshiaki Ito's Student; PhD 2015)
- o. Sun Wendi (Lorenz Pollinger's Student; PhD 2015)
- p. Chau Hau Wing David (Eric Tze's student, University of Hong Kong; PhD 2015)
- q. Wang Ting Ting (Lee Soo Chin's student; PhD 2015)
- r. Kwok Hui Si (Dan Tenen's Student, NGS, PhD 2016)
- s. Chen Ye (Phil Koeffler's Student, CSI, PhD 2016)
- t. Daniel Tan (Dan Tenen's Student, CSI, PhD 2016)

**PUBLICATIONS / BIBLIOGRAPHY [45 as First Author, 50 as last or corresponding author; H-index 29; total citations 3318]**

1. JA Spencer, **WJ Chng**, Hudson E, Boon AP, Whelan P. Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer. *Br J Radiol* 1998; 71:1130-1135. [IF – 1.938; Cited 17 times]
2. **\*WJ Chng**, MA Howard. Pel-Ebstein fever with cyclical pancytopenia. *Journal of Royal Society of Medicine* 2001; 94:84-85. [IF – 1.717]
3. **\*WJ Chng**, CA Henderson. Panniculitis associated with alpha 1-antitrypsin deficiency (PiSZ phenotype) treated with doxycycline. *Br J Dermatol* 2001; 144:1282-83. [IF – 4.162; Cited 19 times]
4. **\*WJ Chng**, LK Tan, TC Liu. Cyclosporin therapy for patients with CRF who developed pure red cell aplasia following EPO therapy. *Am J Kid Dis* 2003; 41:392-395 [IF – 5.417; Cited 34 times]
5. **\*WJ Chng**. Cytarabine Syndrome Revisited. *Br J Haematol* 2003; 122: 875. [IF – 4.942; Cited 5 times]
6. **\*WJ Chng**, MK Tan, P Kuperan. An audit of fresh frozen plasma usage in an acute general hospital in Singapore. *Singapore Medical Journal* 2003; 44: 574-578. [IF – 0.63; Cited 18 times]
7. **\*WJ Chng**, GB Tan, P Kuperan. Establishment of adult peripheral blood lymphocyte subsets reference range in an Asian population using single platform flow cytometry – Influence of age, sex, race and comparison with other published studies. *Clin Diagn Lab Immunol* 2004; 11:168-173. [IF – 2.598; Cited 51 times]
8. **\*WJ Chng**. Tandem bone marrow transplantation in multiple myeloma. *N Engl J Med* 2004; 350:1466 (Letter). [IF – 51.658; Cited 1 time]
9. **\*WJ Chng**, J Chen, S Lim, SM Chong, YK Kueh, SH Lee. Translocation (8;22) – An additional cytogenetic abnormality in cold agglutinin disease associated with B-cell lymphoma. *Cancer Genet Cytogenet.* 2004; 152: 66-69. [IF – 1.929; Cited 7 times]
10. LG Lau, **WJ Chng**, TC Liu. Unnecessary transfusion due to pseudothrombocytopenia. *Transfusion* 2004; 44:801. [IF – 3.528; Cited 15 times]
11. **\*WJ Chng**, T Thamboo. Unusual presentation of neutrophilic eccrine hidradenitis. *Br J Dermatol* 2004; 150: 507-508. [IF – 4.162; Cited 2 times]
12. **\*WJ Chng**, AEJ Yeoh, TC Liu, TC Quah. t(8;14) Mature B Cell (Burkitt) Lymphoma/Leukaemia with Atypical Morphology. *Eur J Haematol* 2004; 73: 386-387. [IF – 2.548; Cited 1 time]
13. **\*WJ Chng**, C Sum, P Kuperan. Causes of isolated prolonged activated partial thromboplastin time (APTT) in an acute general hospital: A guide to fresh frozen plasma (FFP) usage. *Ann Acad Med Singapore* 2004; 33(suppl): S72-S73. (Best poster Finalist) [IF – 1.452]
14. **\*WJ Chng**, HC Lai, L Shen, P Kuperan. Comparison between haematological parameters in severe respiratory syndrome and dengue fever. *Ann Acad Med Singapore* 2004; 33(suppl): S12-S13. (NHG Doctor Award Finalist) [IF – 1.452]
15. LG Lau, **WJ Chng**, TC Liu, LK Tan, KH Ong, MFB Mow, YK Kueh. A clinico-pathologic study of myelodysplastic syndromes at a single Asian institution – Analysis according to both the French-American-British Classification and the International Prognostic Scoring System. *Ann Acad Med Singapore* 2004; 33:589-594. [IF – 1.452; Cited 8 times]
16. **\*WJ Chng**, G Sundar, BMF Mow. Leukaemic infiltrate of choroids. *Eur J Haematol* 2005; 1: 91-92. [IF – 2.548]
17. **\*WJ Chng**, CYC Yip, MB Baliwag, TC Liu. Differential effect of ABO blood group on collagen binding assay. *Blood Coag Fibrinolysis* 2005; 16: 75-79. [IF – 1.285; Cited 5 times]
18. **\*WJ Chng**, HC Lai, E Arul, P Kuperan. Haematological parameters in SARS. *Clin Lab Haem* 2005; 27: 15-20. [IF – 1.388; Cited 2 times]
19. LG Lau, **WJ Chng**, LHC Tan, TC Liu. Malignant pleural effusion in a patient with multiple myeloma. *Diagn Cytopathology* 2005; 32: 171-2. [IF – 1.487; Cited 4 times]
20. **\*WJ Chng**, LHC Tan. Late-onset severe prolonged pancytopenia due to Imatinib in newly diagnosed chronic phase CML. *Leuk Res* 2005; 29: 719-720. [IF – 2.764; Cited 10 times]
21. **WJ Chng**, LG Lau, NM Yusof, BM Mow. Targeted therapy in multiple myeloma. *Cancer Control* 2005; 12: 91-104. [IF – 3.593]

22. **\*WJ Chng.** Treatment of myelodysplastic Syndrome (Letter) *New Engl J Med* 2005; 352: 2134-35 (letter) [IF – 51.658; Cited 2 times]
23. **WJ Chng,** SA Van Wier, G Ahmann, Winkler JM, Jalal SM, Bergsagel PL, Chesi M, Trendle MC, Oken MM, Blood E, Henderson K, Santana-Dávila R, Kyle RA, Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Fonseca R. A validated FISH Trisomy Index Demonstrates the Hyperdiploid and non-hyperdiploid dichotomy in MGUS. *Blood* 2005; 106: 2156-2161. [IF – 9.338; Cited 63 times]
24. A Wong, NM Yusof, SH Tan, **\*WJ Chng.** Diagnosis in Oncology: An unusual presentation of multiple myeloma with cranial nerve palsies. *J Neuro-oncol* 2005; 74:217-218. [IF – 3.194; Cited 1 time]
25. **\*WJ Chng,** C Sum, P Kuperan. Causes of isolated prolonged activated partial prothrombin time in an acute general hospital. *Singapore Med J* 2005; 46:450-456. [IF – 0.63; Cited 10 times]
26. **WJ Chng,** R Fonseca. Genomics in multiple myeloma: biological and clinical implications. *Pharmacogenomics* 2005; 6: 563-573. [IF – 3.857; Cited 7 times]
27. **WJ Chng,** R Fonseca. Risk stratification of newly diagnosed patients with multiple myeloma: optimizing treatment based on pre-treatment characteristics. *Clinical lymphoma myeloma* 2005; 6: 200-207. [IF 1.667; Cited 5 times]
28. **WJ Chng,** VM Winkler, PR Griep, Jalal SM, Bergsagel PL, Chesi M, Trendle MC, Ahmann GJ, Henderson K, Blood E, Oken MM, Hulbert A, Van Wier SA, Santana-Dávila R, Kyle RA, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R. Ploidy Status Rarely Changes in Myeloma Patients at Disease Progression. *Leuk Res* 2006; 30: 266-271 [IF – 2.764; Cited 22 times]
29. **WJ Chng,** A Gualberto, R Fonseca. IGF-1R is over-expressed in poor-prognostic sub-types of MM. *Leukemia* 2006; 20: 174-176. [IF – 10.164; Cited 20 times]
30. **\*WJ Chng.** MicroRNA in chronic lymphocytic leukemia. *N Engl J Med* 2006; 354: 524-525. [IF – 51.658; Cited 10 times]
31. **WJ Chng,** G Ahmann, K Henderson, Santana-Davila R, Greipp PR, Gertz MA, Lacy MQ, Dispenzieri A, Kumar S, Rajkumar SV, Lust JA, Kyle RA, Zeldenrust SR, Hayman SR, Fonseca R. Clinical implication of centrosome abnormalities in Plasma Cell Neoplasm. *Blood* 2006; 107: 3669-3675. [IF – 9.338; Cited 38 times]
32. **WJ Chng,** JM Winkler, SA Van Wier, Ahmann GJ, Jalal SM, Bergsagel PL, Chesi M, Trendle MC, Jacobus S, Blood E, Oken MM, Henderson K, Kyle RA, Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Fonseca R. IgH translocations but not chromosome 13 deletion negatively impact survival in hyperdiploid myeloma. *Leukemia* 2006; 20: 807-813. [IF – 10.164; Cited 62 times]
33. **WJ Chng,** RF Schop, Ghobrial I, Kay N, Jelinek DF, Gertz MA, Dispenzieri A, Lacy M, Kyle RA, Greipp PR, Tschumper RC, Fonseca R, Bergsagel PL. Gene expression profiling of Waldenstroms macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. *Blood* 2006; 108: 2755-2763. [IF – 9.338; Cited 78 times]
34. **\*WJ Chng,** R Ketterling, R Fonseca. Analysis of genetic abnormalities provides insights into genetic evolution of hyperdiploid myeloma. *Genes Chrom Cancer* 2006; 45: 1111-1120. [IF – 3.588; Cited 20 times]
35. R Fonseca, SA Van Wier, **WJ Chng,** Ketterling R, Lacy MQ, Dispenzieri A, Bergsagel PL, Rajkumar SV, Greipp PR, Litzow MR, Price-Troska T, Henderson KJ, Ahmann GJ, Gertz MA. Low level amplification of 1q21 in myeloma and prognosis: the role of CKS1B. *Leukemia* 2006; 20: 2034-2240. [IF – 10.164; Cited 73 times]
36. N Gonzalez-Paz, **WJ Chng,** RF McClure, Blood E, Oken MM, Van Ness B, James CD, Kurtin PJ, Henderson K, Ahmann GJ, Gertz M, Lacy M, Dispenzieri A, Greipp PR, Fonseca R. Tumor suppressor p16 methylation in multiple myeloma: Biological and clinical implications. *Blood* 2007; 109: 1228-1232. [IF – 9.338; Cited 40 times]
37. **\*WJ Chng.** Limits to the Human Cancer Genome Project? *Science* 2007; 315: 762-766. [IF – 33.587; Cited 1 time]
38. **WJ Chng,** N Gonzalez-Paz, T Price-Troska, Van Wier S, Jacobus S, Blood E, Henderson K, Oken M, Van Ness B, Greipp P, Rajkumar SV, Fonseca R. Clinical significance of TP53 mutation in myeloma. *Leukemia* 2007; 21: 582-584. [IF – 10.164; Cited 38 times]
39. G Mulligan, C Mitsiades, B Bryant, F Zhan, **WJ Chng,** Roels S, Koenig E, Fergus A, Huang Y, Richardson P, Trepicchio WL, Broyl A, Sonneveld P, Shaughnessy JD Jr, Bergsagel PL, Schenkein D, Esseltine DL, Boral A, Anderson KC. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. *Blood* 2007; 109: 3177-3188. [IF – 9.338; Cited 100 times]
40. **WJ Chng,** B Bryant, G Mulligan, PL Bergsagel. Survival of genetic subtypes of relapse myeloma may be modulated by secondary events. *Blood* 2007; 109: 3610-3611. [IF – 9.338; Cited 7 times]
41. **\*WJ Chng,** S Kumar, S Van Wier, Ahmann G, Price-Troska T, Henderson K, Chung TH, Kim S, Mulligan G, Bryant B, Carpten J, Gertz M, Rajkumar SV, Lacy M, Dispenzieri A, Kyle R, Greipp P, Bergsagel PL, Fonseca R. Molecular dissection of hyperdiploid myeloma using gene expression profiling. *Cancer Res* 2007; 67: 2982-2989. [IF – 8.65; Cited 77 times]
42. JJ Keats, R Fonseca, M Chesi, RF Schop, A Baker, **WJ Chng,** Van Wier S, Tiedemann R, Shi CX, Sebag M, Braggio E, Henry T, Zhu YX, Fogle H, Price-Troska T, Ahmann G, Mancini C, Brents LA, Kumar S, Greipp P, Dispenzieri A, Bryant B, Mulligan G, Bruhn L, Barrett M,



- Valdez R, Trent J, Stewart AK, Carpten J, Bergsagel PL. Promiscuous mutations activate the non-canonical NF-KB pathway in multiple myeloma. *Cancer Cell* 2007; 12: 131-144. [IF – 27.059; Cited 401 times]
43. **WJ Chng**, O Glebov, PL Bergsagel, WM Kuehl. Genetic events in the pathogenesis of multiple myeloma. *Best Pract Res Clin Haematol* 2007; 20: 571-596. [IF – 2.825; Cited 95 times]
  44. **\*WJ Chng**, E Braggio, R Valdez, G Mulligan, B Bryant, E Remstein, A Dogan, R Fonseca. The centrosome index is a powerful prognostic marker in multiple myeloma and identifies a cohort of patients that may benefit from aurora kinase inhibition. *Blood* 2008; 111: 1603-1609. [IF – 9.338; Cited 42 times]
  45. M Chesi, DF Robbiani, M Sebag, **WJ Chng**, Affer M, Tiedemann R, Valdez R, Palmer SE, Haas SS, Stewart AK, Fonseca R, Kremer R, Cattoretti G, Bergsagel PL. AID-dependent MYC activation induces multiple myeloma in a novel mouse model of post-germinal center malignancies. *Cancer Cell* 2008; 13: 167-180. [IF – 23.2; Cited 144 times]
  46. **\*WJ Chng**, R Fonseca. Cell lines for hyperdiploid multiple myeloma, are we there yet? *Br J Haematol* 2008; 140: 579-580. [IF – 5.4; Cited 2 times]
  47. **\*WJ Chng**, WM Kuehl, PL Bergsagel, R Fonseca. Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature in multiple myeloma. *Leukaemia* 2008; 22: 459-461. [IF – 12.1; Cited 23 times]
  48. GA Ahmann, **WJ Chng**, K Henderson, Price-Troska TL, DeGoey RW, Timm MM, Dispenzieri A, Greipp PR, Sable-Hunt A, Bergsagel L, Fonseca R. Impact of Tissue Shipping on Plasma Cell Isolation, Viability, and RNA Integrity in the Context of a Centralized Good Laboratory Practice Certified Tissue Banking Facility. *Cancer Epidemiol Biomarkers Prev* 2008; 17: 666-673. [IF – 3.6; Cited 9 times]
  49. **WJ Chng**, S Jacobus, R Fonseca. Do beta-2 microglobulin levels affect survival of newly diagnosed myeloma patients with translocation t(4;14) or 17p13 deletion treated with conventional chemotherapy? *Leukemia* 2008; 22: 1080-1081. [IF – 12.1; Cited 2 times]
  50. RE Tiedemann, N Gonzalez-Paz, RA Kyle, R Santana-Davila, T Price-Troska, S Van Wier, **WJ Chng**, Ketterling RP, Gertz MA, Henderson K, Greipp PR, Dispenzieri A, Lacy MQ, Rajkumar SV, Bergsagel PL, Stewart AK, Fonseca R. Genetic Aberrations and Survival in Plasma Cell Leukemia. *Leukemia* 2008; 22: 1044-1052. [IF – 12.1; Cited 124 times]
  51. ML Poon and **\*WJ Chng**. Is complete remission an important therapeutic aim in multiple myeloma. *Cancer Therapy* 2008; 6: 275-284.
  52. **WJ Chng**, N Gonzalez-Paz, T Price-Troska, Jacobus S, Rajkumar SV, Oken MM, Kyle RA, Henderson KJ, Van Wier S, Greipp P, Van Ness B, Fonseca R. Clinical and Biological Significance of RAS mutations in Multiple Myeloma. *Leukemia* 2008; 22: 2280-2284. [IF – 12.1; Cited 75 times]
  53. O'Neal J, Gao F, Hassan A, Monahan R, Barrios S, Lee I, **WJ Chng**, Vij R, Tomasson MH. Neurobeachin (NBEA) is a target of recurrent interstitial deletions at 13q13 in patients with MGUS and multiple myeloma. *Exp Hematol* 2009; 37: 234-244. [IF – 2.3; Cited 21 times]
  54. **WJ Chng**, ED Remstein, R Fonseca, Bergsagel PL, Vrana JA, Kurtin PJ, Dogan A. Gene Expression Profiling of Pulmonary Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Identifies New Diagnostic Markers, Biological Heterogeneity and Potential Therapeutic Targets. *Blood* 2009; 113: 635-645. [IF – 11.8; Cited 23 times]
  55. JB Zhou, C Bi, JV Janakakumara, SC Liu, **WJ Chng**, KG Tay, LF Poon, Z Xie, S Palanyandi, H Yu, Glaser KB, DH Albert, SK Davidsen, CS Chen. Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. *Blood* 2009; 113: 4052-4062. [IF – 11.8; Cited 84 times]
  56. **WJ Chng**, R Fonseca. Centrosomes in myeloma, aneuploidy and proliferation. *Environ Mol Mutagen* 2009; 50: 697-707. [IF – 3.3; Cited 11 times]
  57. SC Lee, X Xu, **WJ Chng**, Watson M, Lim YW, Wong CI, Iau P, Sukri N, Lim SE, Yap HL, Buhari SA, Tan P, Guo J, Chuah B, McLeod HL, Goh BC. Post-treatment Tumor Gene Expression Signatures are more Predictive of Treatment Outcome than Baseline Signatures in Breast Cancer. *Pharmacogenet Genomics* 2009; 19: 833-842. [IF – 2.9; Cited 10 times]
  58. JT Yustein, YC Liu, P Gao, C Jie, M Vuica-Ross, **WJ Chng**, PL Bergsagel, C Dang. Putative ectopic Myc target genes in a human B cell neoplastic model: Induction of JAG2 by MYC augments hypoxic growth and tumorigenesis. *Proc Natl Acad Sci U S A* 2010; 107:3534-3539. [IF – 9.4; Cited 31 times]
  59. Ng ES, Aw DC, Tan KB, Poon ML, Yap ES, Liu TC, Tan LK, **Chng WJ**, Koh LP. Neutrophilic Eccrine Hidradenitis associated with Decitabine. *Leuk Res* 2010; 34: e130-132 [IF – 2.6; Cited 6 times]
  60. **WJ Chng**, Gertz MA, Chung TH, Van Wier S, Keats JJ, Baker A, Bergsagel PL, Carpten J, Fonseca R. Correlation between Array-Comparative Genomic Hybridization Defined Genomic Gains and Losses and Survival: Identification of 1p31-32 deletion as a prognostic factor in myeloma. *Leukemia* 2010; 24: 833-842. [IF – 12.1; Cited 27 times]
  61. H Wang, L Vardy, JM Loo, Loo JM, Guo K, Li J, Lim SG, Zhou J, **WJ Chng**, HX Li, Q Zeng. PCBPI suppresses the translation of metastasis-associated PRL-3 phosphatase. *Cancer Cell* 2010; 18: 52-62. [IF – 23.2; Cited 62 times]

62. **\*WJ Chng**. Micro-managing the miRNome in Sezary Syndrome. *Blood* 2010; 116:1021-1022. [IF – 11.8; Cited 1 time]
63. Z Xie, **WJ Chng**, KG Tay, SC Liu, J Zhou, CS Chen. Therapeutic potential of antisense oligodeoxynucleotides in downregulating p53 oncogenic mutations in cancers. *Biotechnol Lett* 2010; 33: 221-228. [IF – 1.6; Cited 2 time]
64. M Yang, Wang FD, Han B, Wang SJ, Zhou DB, Pan H, Zhao YQ, Cui QC, Ma L, **WJ Chng**, T Shen. Castleman's disease presenting as prolonged anemia and growth retardation: a case report and literature review. *Acta Haematologica* 2011; 125: 125-129. [IF – 1.1; Cited 2 times]
65. SB Ng, Selvarajan V, Huang G, Zhou J, Feldman AL, Law M, Kwong YL, Shimizu N, Kagami Y, Aozasa K, Salto-Tellez M, **\*WJ Chng**. Gene expression profiling reveals activation of multiple oncogenic pathways and over-expression of survivin in the pathogenesis of extranodal nasal-type NK/T cell lymphoma. *J Pathol* 2011; 223: 496-510. [IF - 7.4; Cited 52 times]
66. **\*WJ Chng**, Huang GF, Chung TH, Ng SB, Gonzalez-Paz N, Troska-Price T, Mulligan G, Chesi M, Bergsagel PL, Fonseca R. Clinical and biological implications of MYC activation: A common difference between MGUS and newly diagnosed multiple myeloma. *Leukemia* 2011; 25: 1026-35 [IF – 12.1; Cited 91 times]
67. Zhou J, Bi C, **\*Chng WJ**, Cheong LL, Liu SC, Mahara S, Tay KG, Zeng Q, Li J, Guo K, Tan CP, Yu H, Albert DH, Chen CS. PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signalling and implicated in anti-AML therapy. *PLOS One* 2011; 6: e19798. [IF 3.1; Cited 23 times; Faculty 1000]
68. Xie Z, Bi C, Cheong LL, Liu SC, Huang G, Zhou J, Yu Q, Chen CS, **\*WJ Chng** et al. Determinants of sensitivity to DZNep induced apoptosis in multiple myeloma cells. *PLOSone* 2011; 6: e21583. [IF 3.1; Cited 19 times]
69. Ng APP, **WJ Chng**, Khan M. Curcumin sensitizes acute promyelocytic leukemia cells to unfolded protein response-induced apoptosis by blocking the loss of misfolded N-CoR protein. *Mol Cancer Res* 2011; 9: 878-888 [IF 4.5; Cited 14 times]
70. Zhou J, Bi C, Cheong LL, Mahara S, Liu SC, Tay KG, Koh TL, Yu Q, **\*WJ Chng**. The histone methyltransferase inhibitor, DZNep, upregulates TXNIP, increases ROS production and targets leukaemia cells in AML. *Blood* 2011; 118: 2830-2839. [IF 11.8, Cited 82 times].
71. R Kannaiyan, Hay HS, Rajendran P, Li F, Shanmugam MK, Vali S, Abbasi T, Kapoor S, Sharma A, Kumar AP, **\*Chng WJ**, Sethi G. Celestrol inhibits proliferation and induces chemosensitization through downregulation of NF-KB and STAT3 regulated gene products in multiple myeloma cells. *Br J Pharmacol* 2011; 164: 1506-1521. [IF 5.3; Cited 46 times]
72. J Zhou, Q Yu, **WJ Chng\***. TXNIP (VDUP-1, TBP-2): A Major Redox Regulator Commonly Suppressed in Cancer by Epigenetic Mechanisms. *Int J Biochem Cell Biol.* 2011; 43: 1668-1673. [IF 3.9; Cited 25 times]
73. Bi CL, **Chng WJ\***. miRNA deregulation in multiple myeloma. *Chin Med J* 2011; 124: 3164-9. [IF 1.0; Cited 5 times].
74. Ng SB, Yan J, Huang G, Selvarajan V, Tay JL, Lin B, Bi C, Tan J, Kwong YL, Shimizu N, Aozasa K, **\*WJ Chng**. Dysregulated MicroRNAs Affect Pathways and Targets of Biological Relevance in Nasal-type Natural Killer / T-cell Lymphoma. *Blood* 2011; 118: 4919-29 [IF 11.8; cited 40 times].
75. S Hart, KC Goh, V Novotny-Diemayr, YC Tan, B Madanm C Amalini, LC Ong, BK Ng, A Cheong, J Zhou, **WJ Chng**, JM Wood. Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukaemia. *Blood Cancer J* 2011; 1: e44. [IF – 4.4; Cited 19 times]
76. JH Chai, Y Zhang, WH Tan, **WJ Chng**, B Li, X Wang. Regulation of hTERT by BCR-ABL at multiple levels in K562 cells. *BMC Cancer* 2011; 11: 512. [IF 3.3; Cited 10 times]
77. KB Tan, LU Ling, **WJ Chng**, GNC Chiu. In vivo Efficacy of a Novel Liposomal Formulation of Safingol in the Treatment of Acute Myeloid Leukemia. *Journal of Control Release* 2012; 160: 290-298 [IF 7.4; Cited 15 times].
78. E Braggio, A Dogan, JJ Keats, **WJ Chng**, Huang G, Matthews JM, Maurer MJ, Law ME, Bosler DS, Barrett M, Lossos IS, Witzig TE, Fonseca R. Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities. *Mod Pathol.* 2012; 25: 651-660. [IF 5.5; Cited 26 times]
79. Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O, Terpos E, Munshi N, Palumbo A, Rajkumar SV, Harousseau JL, Moreau P, Avet-Loiseau H, Lee JH, Cavo M, Merlini G, Voorhees P, **Chng WJ**, Mazumder A, Usmani S, Einsele H, Comenzo R, Orlowski R, Vesole D, Lahuerta JJ, Niesvizky R, Siegel D, Mateos MV, Dimopoulos M, Lonial S, Jagannath S, Bladé J, Miguel JS, Morgan G, Anderson KC, Durie BG, Sonneveld P. Management of treatment-emergent peripheral neuropathy in multiple myeloma. *Leukemia* 2012; 26: 595-608. [IF – 12.1; Cited 81 times]
80. D Chan, J Tyner, **WJ Chng**, R Okamoto, J Said, HP Koeffler. In vitro and in-vivo study of Dasatinib: Effect against thyroid cancer cell lines. *Oncology Letters* 2012; 3: 807-815. [IF 1.5; Cited 2 times]
81. Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, Teo AS, Ariyaratne PN, Takahashi N, Sawada K, Fei Y, Soh S, Lee WH, Huang JW, Allen JC Jr, Woo XY, Nagarajan N, Kumar V, Thalamuthu A, Poh WT, Ang AL, Mya HT, How GF, Yang LY, Koh LP, Chowbay B, Chang

- CT, Nadarajan VS, **Chng WJ**, Than H, Lim LC, Goh YT, Zhang S, Poh D, Tan P, Seet JE, Ang MK, Chau NM, Ng QS, Tan DS, Soda M, Isobe K, Nöthen MM, Wong TY, Shahab A, Ruan X, Cacheux-Rataboul V, Sung WK, Tan EH, Yatabe Y, Mano H, Soo RA, Chin TM, Lim WT, Ruan Y, Ong ST. A Common Deletion Polymorphism in the BIM Gene Contributes to Intrinsic Resistance to Imatinib in Chronic Myelogenous Leukemia. *Nat Med* 2012; 18 521-8. [**IF – 30.4; Cited 233 times**]
82. K Guo, JP Tang, Jie L, Al-Aidaros AQ, Hong CW, Tan CP, Park JE, Varghese L, Feng Z, Zhou J, **Chng WJ**, Zeng Q. Engineering the First Chimeric Antibody in Targeting Intracellular PRL-3 Oncoprotein for Cancer Therapy in Mice. *Oncotarget* 2012; 3: 158-71. [**IF 5.0, Cited 24 times**]
83. DS Nin, WK Kok, F Li, S Takahashi, **WJ Chng**, M Khan. Role of misfolded N-CoR mediated Transcriptional Dereglulation of FLT3 in Acute Monocytic Leukemia (AML)-M5 Subtype. *PLoSone* 2012; 7:e34501 [**IF – 3.1; Cited 5 times**]
84. Tse E, Gill H, Loong F, Kim SJ, Ng SB, Tang T, Ko YH, **Chng WJ**, Lim ST, Kim WS, Kwong YL. Type II enteropathy associated T-cell lymphoma: a retrospective multi-center analysis from the Asia Lymphoma Study Group. *Am J Hematol* 2012; 87: 663-668. [**IF – 5.0, Cited 35 times**]
85. D Tan, KH Ong, LP Koh, SS Wong, MT Khin, LH, Lee, YT Goh, **WJ Chng**. The Impact of Frontline risk-adapted strategy on the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma: An Analysis of the Singapore Multiple Myeloma Study Group. *Eur J Haematol* 2012; 89: 136-144. [**IF – 2.5; Cited 13 time**]
86. L Chu, MY Su, L Maggi, L Lu, C Mullins, S Crosby, G Huang, **WJ Chng**, R Vij, MH Tomasson. Multiple myeloma-associated chromosomal translocation activates orphan snoRNA ACA11 to suppress oxidative stress. *J Clin Invest* 2012; 122: 2793-806. [**IF – 12.8; Cited 22 times**]
87. LM Poon, J Jin, YL Chee, Y Ding, YM Lee, **WJ Chng**, LYA Chai, LK Tan, LY Hsu. Risk factors for adverse outcomes and multidrug-resistant Gram-negative bacteremia in hematology patients with febrile neutropenia in a Singaporean university hospital. *SMJ*. 2012; 53:720-725. [**IF – 0.6; Cited 13 time**]
88. Zhou J, Cheong LL, Liu SC, Chong PS, Mahara S, Bi C, Ong KO, Zeng Q, **\*Chng WJ**. The pro-metastasis tyrosine phosphatase, PRL-3 (PTP4A3), is a novel mediator of oncogenic function of BCR-ABL in human chronic myeloid leukemia. *Mol Cancer* 2012; 11: 72 [**IF – 5.9; Cited 5 times**].
89. A Ghosh, G Saginc, SC Leow, E Khattar, EM Shin, TD Yan, M Wong, Z Zhang, G Li, WK Sung, J Zhou, **WJ Chng**, S Li, E Liu, V Tergaonkar. Telomerase directly regulates NFκB dependent transcription. *Nat Cell Biol* 2012; 14: 1270-1281 [**IF – 18.7; Cited 86 times**]
90. TH Chung, **\*WJ Chng**. Clinical utility and implementation of gene expression profiling in myeloma: current status and challenges. *Int J Hematol Oncol* 2012; 1: 133-146.
91. P Panneerselvam, S Ye, GLW Choon, V Selvarajan, **WJ Chng**, SB Ng, NS Tan, B Ho, J Chen, JL Ding. T cell lymphoma is linked to the loss of proapoptotic function of SARM1. *Cell Death Differentiation* 2013; 20: 478-489. [**IF – 8.2; Cited 23 times**]
92. Zhou JB, Ng SB, **\*Chng WJ**. LIN28/LIN28B: An Emerging Oncogenic Driver in Cancer Stem Cells. *Int J Biochem Cell Biol*. 2013; 45: 973-978. [**IF 3.9; Cited 37 time**]
93. S Hart, V Novotny-Diermayr, KC Goh, M Williams, YC Tan, LC Ong, A Cheong, BK Ng, C Amalini, B Madan, H Nagaraj, R Jayaraman, KM Pasha, K Ethirajulu, **WJ Chng**, N Mustafa, BC Goh, CH Benes, U McDermott, MJ Garnett, B Dymock, JM. Wood. VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer. *Mol Cancer Ther* 2013; 12: 151-161. [**IF 5.6; Cited 17 times**]
94. JB Zhou, **\*WJ Chng**. Role of TXNIP (VDUP-1, TBP-2) in Oxidative Stress, Apoptosis and Cancer. *Mitochondrion*. 2013; 13: 163-169 [**IF – 3.6; Cited 21 times**]
95. Coxford JL, Pan MF, Tang MLF, Huang CW, Kamran N, Phua CML, **Chng WJ**, Ng SB, Raulet DH, S Gasser. T Cell-Dependent Spontaneous Regression of Early Emu-myc-induced B-cell leukaemia. *Blood* 2013; 121: 2512-2521. [**IF – 11.8; Cited 23 time**]
96. Huo J, Xu S, Lin B, **Chng WJ**, Lam KP. Fas-Apoptosis Inhibitory Molecule (FAIM) is up-regulated by IGF-1 signaling and modulates AKT Activation and IRF-4 expression in Multiple Myeloma. *Leukemia* 2013; 27: 1165-71 [**IF – 12.1; Cited 6 time**].
97. SY Tan, SS Chuang, T Tang, L Tan, HY Ko, KL Chuah, SB Ng, **WJ Chng**, K Gatter, F Leong, YH Liu, P Hosking, PL Cheah, BH Teh, K Tay, M Koh, ST Lim. Type II EATL (Epitheliotropic Intestinal T-cell Lymphoma): a neoplasm of intra-epithelial T-cells with predominant CD8αα phenotype. *Leukemia*. 2013; 27: 1688-1696 [**IF – 12.1; Cited 24 time**].
98. J Yan, SB Ng, JL Tay, B Lin, TL Koh, J Tan, V Selvarajan, SC Liu, C Bi, S Wang, SN Choo, N Shimizu, G Huang, Q Yu and **\*WJ Chng**. EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity. *Blood* 2013; 121: 4512-4520. [**IF – 11.8; Cited 20 time**]
99. TH Chung, G Mulligan, R Fonseca, **\*WJ Chng**. A novel measure of chromosome instability can account for prognostic difference in multiple myeloma. *PLoS ONE* 2013; 8: e66361 [**IF – 3.1; Cited 12 time**]
100. Jimenez-Zepeda VH, **Chng WJ**, Schop RF, Braggio E, Leis JF, Kay N, Fonseca R. Recurrent chromosome abnormalities define nonoverlapping unique subgroups of tumors in patients with

- chronic lymphocytic leukemia and known karyotypic abnormalities. *Clin Lymphoma Myeloma Leuk*. 2013; 13: 467-76. [IF – 2.3]
101. AQO Al-Aidaros, HF Yuen, K Guo, SD Zhang, TH Chung, **WJ Chng**, Q Zeng. PRL-3 Induces EGFR Activation and Addiction in Human Cancer Cells. *J Clin Invest* 2013; 123: 3459-71. [IF – 12.6; cited 21 times]
  102. D Chan, Y Zheng, J Tyner, **WJ Chng**, WW Chien, G Braunstein, HP Koeffler. Belinostat and Panobinostat (HDACI): In vitro and in vivo Studies in Thyroid Cancer. *J Cancer Res Clin* 2013; 139: 1507-14. [IF – 3.1; Cited 8 times]
  103. Z Xie, J Gunaratne, LL Cheong, SC Liu, TL Koh, G Huang, W Blackstock, **\*WJ Chng**. Plasma Membrane Proteomics Identifies Biomarkers Associated with t(4;14) Multiple Myeloma. *Oncotarget* 2013; 4: 1008-18. [IF – 5.0; Cited 5 times]
  104. D Tan, K Kim, JS Kim, HS Eom, G Teoh, KH Ong, YT Goh, BGM Durie, **WJ Chng**, JH Lee. The Impact of Upfront Versus Sequential Use of Bortezomib among Patients with Newly Diagnosed Multiple Myeloma (MM): A Joint Analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian Myeloma Network. *Leuk Res* 2013; 37: 1070-6. [IF – 2.6; Cited 7 times]
  105. Jung Eun Park, Hiu-Fung Yuen, Abdul Qader O. Al-Aidaros, Ke Guo, Jianbiao Zhou, Shudong Zhang, Ken Mills, **WJ Chng** and Qi Zeng. An oncogenic role of PRL-3 in FLT3-ITD Induced Acute Myeloid Leukemia. *EMBO Mol Med* 2013; 5: 1351-66. [IF – 9.5; cited 10 times]
  106. J Yan, G Huang, N Jiang, B Lin, JLS Tay, C Bi, GS Koh, J Tan, Y Lu, SK Kham, AEJ Yeoh, **\*WJ Chng**. Deregulated miR-335 that Targets MAPK1 is Implicated in Poor Outcome of Paediatric Acute Lymphoblastic Leukaemia. *Br J Haematol* 2013; 163: 93-103. [IF – 5.4; Cited 15 time]
  107. DS Nin, AB Ali, K Okumura, N Asou, **WJ Chng**, M Khan. AKT induced N-CoR phosphorylation is linked to its misfolded conformation dependent loss in acute myeloid leukaemia (AML)-M5 subtype. *PLoS One* 2013; 8: e70891. [IF – 3.1; Cited 2 times]
  108. R Reghunathan, C Bi, SC Liu, TL Koh, TH Chung, G Huang, SL Chan, and **\*WJ Chng**. Clonogenic multiple myeloma cells have shared stemness signature that is associated with patient outcome. *Oncotarget* 2013; 4: 1230-1240. [IF – 5.0; Cited 15 times]
  109. Kim SJ, Hsu C, Song YQ, Tay K, Hong XN, Cao J, Kim JS, Eom HS, Lee JH, Zhu J, Chang KM, Reksodiputro AH, Tan D, Goh YT, Lee J, Intragumtornchai T, **Chng WJ**, Cheng AL, Lim ST, Suh C, Kwong YL, Kim WS. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group. *Eur J Cancer* 2013; 49: 3486-96. [IF – 6.2; Cited 41 times]
  110. D Tan, **WJ Chng**, T Chou, W Nawarawong, J Hwang, CS Chim, Wenming C, BGM, Durie, JH Lee. Management of Multiple Myeloma in Asia: Consensus Statement from the Asian Myeloma Network. *Lancet Oncol* 2013; 14: e571-581. [IF – 26.5; cited 9 times]
  111. SJ Kim, HA Jung, SS Chuang, Y Song, J Zhu, J Cao, X Hong, R Suzuki, HJ Kang, JH Won, **WJ Chng**, YL Kwong, C Suh, CC Guo, K Tay, ST Lim, J Suzumiya, TY Lin, WS Kim. Multicenter retrospective analysis of patients with extranodal natural killer/T-cell lymphoma in the gastrointestinal tract. *J Hematol Oncol*. 2013; 6: 86. [IF – 6.3; Cited 11 times]
  112. K Kudo, C Imai, P Lorenzini, T Kamiya, K Kono, A Davidoff, **WJ Chng**, D Campana. A Chimeric Receptor That Triggers Antibody-Dependent Cell Cytotoxicity Against Multiple Tumors in T Lymphocytes. *Cancer Res* 2014; 74: 93-103. [IF – 8.6; Cited 22 times]
  113. **\*WJ Chng**, A Dispenzieri, CS Chim, R Fonseca, H Goldschmidt, S Lentzsch, N Munshi, A Palumbo, J San Miguel, P Sonneveld, S Umami, BDG Durie, H Avet-Loiseau on Behalf of the International Myeloma Working Group. IMWG Consensus on Risk Stratification in Multiple Myeloma. *Leukemia* 2014; 28: 269-77. [IF – 12.1; Cited 79 times]
  114. EHL Chan, SJ Lu, F Petersson, KB Tan, **\*WJ Chng**, SB Ng. Unusual case of metachronous EBV-associated B-cell and NK/T-cell lymphoma mimicking polymyositis – Diagnostic challenges and pitfalls. *Am J Haem* 2014; 89:110-113. [IF – 5.0]
  115. E Ocio, P Richardson, S Rajkumar, A Palumbo, MV Mateos, R Orłowski, S Kumar, S Usmani, GD Roodman, R Niesvizky, H Einsele, KC Anderson, M Dimopoulos, H Avet-Loiseau, UH Mellqvist, I Turesson, G Merlini, R Schots, P McCarthy, P.L. Bergsagel, CS Chim, JJ Lahuerta, J Shah, T Reiman, J Mikhael, S Zweegman, S Lonial, R Comenzo, **WJ Chng**, P Moreau, P Sonneveld, H Ludwig, BG Durie, and J San Miguel. New Drugs and Novel Mechanisms of Action in Multiple Myeloma in 2013: A Report from the International Myeloma Working Group (IMWG). *Leukemia* 2014; 28: 525-42. [IF – 12.1; Cited 82 times]
  116. KC Cheng, SC Wong, YC Linn, LP Ho, **WJ Chng**, H Schwarz. CD137 ligand signalling induces differentiation of primary acute myeloid leukemia cells. *Br J Haematol* 2014; 165: 134-144. [IF – 5.4; Cited 2 times]
  117. YP Zhou, J Jin, Y Ding, YL Chee, LP Koh, **WJ Chng**; DSG Chan, LY Hsu. Direct costs associated with febrile neutropenia in inpatients with hematological diseases in Singapore. *Support Care Cancer* 2014; 22: 1447-51. [IF - 2.5; Cited 3 times]
  118. KB Tan, LU Ling, RM Bunte, **WJ Chng**, GNC Chiu. Liposomal co-delivery of a synergistic combination of bioactive lipids in the treatment of acute myeloid leukemia. *Nanomedicine* 2014; 9: 1665-79. [IF – 4.9; Cited 1 time]

119. KS Siveen, N Mustaffa, F Li, R Kannaiyan, KS Ahn, AP Kumar, **\*WJ Chng**, G Sethi. Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF- $\kappa$ B regulated gene products in multiple myeloma xenograft mouse model. *Oncotarget* 2014; 5: 634-48. [IF – 5.0; Cited 16 times]
120. E Tse, TSY Chan, LP Koh, **WJ Chng**, WS Kim, T Tang, ST Lim, AKW Lie, YL Kwong. Allogeneic haematopoietic stem cell transplantation for natural killer/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group. *Bone Marrow Transplant* 2014; 49: 902-906. [IF – 3.6; Cited 9 times]
121. LA Gole, A Lin, C Chua, **WJ Chng**. Modified cIg-FISH Protocol For Multiple Myeloma For Routine Cytogenetic Laboratory Practice. *Cancer Genet* 2014; 207: 31-34. [Cited 3 times]
122. PJ Teoh, TH Chung, C Sintosebastian, J Yan, SB Ng, R Fonseca, **\*WJ Chng**. p53 haploinsufficiency and functional abnormalities in multiple myeloma. *Leukemia* 2014. 28: 2066-74. [IF – 12.1; Cited 13 times]
123. PSY Chong, J Zhou, LL Cheong, SC Liu, J Qian, T Guo, SK Sze, Q Zeng, **\*WJ Chng**. LEO1 is Regulated by PRL-3 and Mediates Its Oncogenic Properties in Acute Myeloid Leukemia. *Cancer Res* 2014; 74: 3043-3053. [IF – 8.5; Cited 5 times]
124. K Kim, JH Lee, JS Kim, CK Min, SS Yoon, K Shimizu, T Chou, H Kosugi, K Suzuki, W Chen, J Hou, J Lu, XJ Huang, SY Huang, **WJ Chng**, D Tan, G Teoh, J Chim, W Nawarawong, N Siritanaratkul, BG Durie. Clinical profiles of multiple myeloma in Asia - an Asian Myeloma Network (AMN) study. *Am J Hem* 2014; 89: 751-9. [IF – 5.0; Cited 11 times]
125. Bi C, **\*Chng WJ**. MicroRNA: Important Player in the Pathobiology of Multiple Myeloma. *Biomed Res Int.* 2014; 2014: 521586. [IF 2.1; Cited 5 times]
126. PJ Teoh and **\*WJ Chng**. P53 abnormalities and potential therapeutic targeting in multiple myeloma. *Biomed Res Int.* 2014; 2014: 717919. [IF 2.1; Cited 3 times]
127. Z Xie, **\*WJ Chng**. MMSET: role and therapeutic opportunities in multiple myeloma. *Biomed Res Int.* 2014; 2014: 636514. [IF 2.1; Cited 2 times]
128. S Widanalage, SH Lim, ML Tung, **\*WJ Chng**. Clinical and Biological Implication of Heterogeneity in Multiple Myeloma. *Biomed Res Int* 2014; 2014: 232546. [IF 2.1; Cited 3 times]
129. J Zhou, LL Cheong, C Bi, PSY Chong, SC Liu, Y Zhou, Xiao Lu, Q Zeng, and **\*WJ Chng**. Phosphatase of regenerating liver-3 is regulated by signal transducer and activator of transcription 3 in acute myeloid leukemia. *Exp Haematol* 2014; 42: 1041-1052. [IF 2.3; Cited 2 times; Selected for Editorial Comments in Journal]
130. L Zhang, AD Jeyasekharan, WS Hsieh, K Ichiyama, DQ Tan, M Ye, B Pang, X Liu, S Widanalage, **WJ Chng**, A Ryo, Y Suzuki, KG Yeoh and N Yamamoto. Combination of Vaccine-Strain Measles and Mumps Virus Synergistically Kills a Wide Range of Human Hematological Cancer Cells: Special Focus on Acute Myeloid Leukemia. *Cancer Letters* 2014; 354: 272-280. [IF 6.0; Cited 1 time]
131. J Zhou\*, and **WJ Chng\***. Identification and Targeting Leukemia Stem Cells: the Path to the Cure for Acute Myeloid Leukemia. *World J Stem Cells* 2014; 6: 473-484.
132. SB Ng, O Koichi, V Selvarajan, G Huang, SN Choo, H Miyoshi, S Wang, HC Chua, AE Yeoh, TC Quah, LP Koh, PL Tan, and **\*WJ Chng**. Prognostic implication of morphology cyclinE2 and proliferation in EBV-associated T/NK lymphoproliferative disease in non-immunocompromised hosts. *Orphanet J Rare Dis* 2014; 9: 165
133. XL Li, J Zhou, Z Chen and **\*WJ Chng**. The role of p53 tumor suppressor in molecular pathogenesis of colorectal cancer and pharmacological reactivation of p53 as cancer therapy. *World J Gastro* 2015; 21: 84-93. [IF 2.8; Cited 10 times]
134. Takata K, Hong ME, Sitthinamsuwan P, Loong F, Tan SY, Liao JY, Hsieh PP, Ng SB, Yang SF, Pongpruttipan T, Sukpanichnant S, Kwong YL, Hsieh Ko Y, Cho YT, **Chng WJ**, Matsushita T, Yoshino T, Chuang SS. Primary cutaneous NK/T-cell lymphoma, nasal type and CD56-positive peripheral T-cell lymphoma: a cellular lineage and clinicopathological study of 61 patients from Asia. *Am J Surg Pathol* 2015; 39: 1-12. [IF 5.0; Cited 7 times]
135. S Kumar, B LaPlant, **WJ Chng**, JA Zonder, NS Callander, R Fonseca, B Fruth, V Roy, C Erlichman, and A Stewart. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single agent activity in patients with relapsed multiple myeloma. *Blood* 2015; 125: 443-448. [IF 11.8; Cited 19 times]
136. Lee DS, Chng WJ, Shimizu K. Plasma cell neoplasms: genetics, pathobiology, and new therapeutic strategies. *Biomed Res Int.* 2014; 2014: 941820. [IF 2.1]
137. M Garg, R Okamoto, Y Nagata, D Kanojia, SMTA Venkatsan, GD Braunstein, JW Said, NB Doan, Q Ho, T Akagi, S Gery, LZ Liu, KT Tan, **WJ Chng**, H Yang, S Ogawa, HP Koeffler. Establishment and characterization of novel human primary and metastatic anaplastic thyroid cancer (ATC) cell lines and their genomic evolution over a year as a primagraft. *J Clin Endocrinol Metab.* 2015; 100: 725-35. [IF 5.5; Cited 2 times]
138. C Wang, D Chin, JY Chooi, **WJ Chng**, I Taniuchi, V Tergaonkar, and M Osato. Cbfb deficiency results in differentiation blocks and stem/progenitor cell expansion in hematopoiesis. *Leukemia* 2015; 29: 753-7. [IF 12.1; Cited 4 times]
139. Yan B, Ban K, **Chng WJ**. Clonal hematopoiesis and blood-cancer risk. *N Engl J Med.* 2015; 372: 1071. [IF 59.6 ; Cited 1 time]

140. JB Zhou, YQ Ching, WJ Chng. Aberrant Nuclear Factor-kappa B in Acute Myeloid Leukemia: From Molecular Pathogenesis to Therapeutic Target. *Oncotarget*. 2015; 6: 5490-5500. [IF 5.0; Cited 2 times]
141. Jiang X, Lim CZ, Li Z, Lee PL, Yatim SM, Guan P, Li J, Zhou J, Pan J, **Chng WJ**, Chai CL, Yu Q. Functional Characterization of D9, a Novel Deazaneplanocin A (DZNep) Analog, in Targeting Acute Myeloid Leukemia (AML). *PLOS One* 2015; 10: e0122983. [IF 3.1; Cited 2 times]
142. X Xing, TJ Flotte, ME Law, AJ Blahnik, **WJ Chng**, G Huang, RA Knudson, RP Ketterling, JC Porcher, SM Ansell, J Siddhu, A Dogan, **AL Feldman**. Expression of the Chemokine Receptor Gene, CCR8, is associated with DUSP22 Rearrangements in Anaplastic Large Cell Lymphomas. *Appl Immunohistochem and Mol Morphol*. 2015; 23: 580-589. [IF – 1.82; Cited 1 time]
143. SB Ng, V Selvarajan, G Huang, SN Choo, R Reghunathan, N Shimizu, S Wang, HC Chua, AE Yeoh, TC Quah, LP Koh, PL Tan, \***WJ Chng**. EBV-associated T/NK-Cell lymphoproliferative disorders in children has similar molecular signature to extranodal NKTCL but shows distinctly stem-cell like phenotype. *Leuk Lymphoma*. 2015; 56: 2408-2415. [IF 3.1; Cited 1 time]
144. Lim JH, Ravikumar S, Wang YM, Thamboo TP, Ong L, Chen J, Goh JG, Tay SH, Chengchen L, Win MS, Leong W, Lau T, Foo R, Mirza H, Tan KS, Sethi S, Khoo AL, **Chng WJ**, Motomi O, Netea MG, Wang Y, Chai LY. Bimodal Influence of Vitamin D in Host Response to Systemic Candida Infection – Vitamin D Dose Matters. *J Infect Dis*. 2015; 212: 635-44. [IF 6.3]
145. Kong LR, Chua KN, Sim WJ, Ng HC, Bi C, Ho J, Nga ME, Pang YH, Ong WR, Soo RA, Huynh H, **Chng WJ**, Thiery JP, Goh BC. MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma. *Mol Cancer Ther* 2015; 14: 1750-60. [IF 5.6; Cited 3 times]
146. K Venkatakrisnan, TM Kim, CC Lin, LS Thye, **WJ Chng**, B Ma, MH Chen, X Zhou, H Liu, V Kelly, WS Kim. Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian patients: pharmacokinetic and recommended phase 2 dose. *Inv New Drugs* 2015; 33: 942-53. [IF 3.3; Cited 4 times]
147. Z Xie, C Bi, JY Chooi, ZL Chan, N Mustafa, and \***WJ Chng**. MMSET regulates transcription factors critical for survival of t(4;14) myeloma myeloma cells and its silence potentiates the effect of antimyeloma agents. *Leukemia* 2015; 29: 2347-54 [IF 12.1; Cited 1 time]
148. RM Foo, ML Tung, LM Poon, D Chan, N Smitasin, LP Koh, **WJ Chng**, LYA Chai. Necrotizing Fasciitis in Haematological Patients: Enterobacteriaceae Predominance and Limited Utility of LRINEX Score. *Open Forum Infectious Diseases*. 2015; 2:ofv081
149. C Bi, TH Chung, G Huang, J Zhou, J Yan, \***WJ Chng**. Genome-wide Pharmacologic Unmasking Identifies Tumor Suppressive MicroRNAs That Are Biologically and Clinically Important in Multiple Myeloma. *Oncotarget* 2015; 6: 26508-18. [IF 5.0; Cited 2 times]
150. N Gupta, YT Goh, CK Min, JH Lee, K Kim, R Wong, CS Chim, MJ Hanley, H Yang, K Venkatakrisnan, AM Hui, DL Esseltine, **WJ Chng**. Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. *J Hem Onc* 2015; 8: 103. [IF 6.3; Cited 4 times]
151. X Li, J Zhou, ZL Chan, JY Chooi, ZR Chen, \***WJ Chng**. PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms. *Oncotarget* 2015; 6: 36689-36699. [IF 5.0; Cited 1 time]
152. Garg M, Nagata Y, Kanojia D, Mayakonda A, Yoshida K, Haridas Keloth S, Zang ZJ, Okuno Y, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ding LW, Alpermann T, Sun QY, Lin DC, Chien W, Madan V, Liu LZ, Tan KT, Sampath A, Venkatesan S, Inokuchi K, Wakita S, Yamaguchi H, **Chng WJ**, Kham SK, Yeoh AE, Sanada M, Schiller J, Kreuzer KA, Kornblau SM, Kantarjian HM, Haferlach T, Lill M, Kuo MC, Shih LY, Blau IW, Blau O, Yang H, Ogawa S, Koeffler HP. Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. *Blood* 2015; 126: 2491-501. [IF 11.8; Cited 3 times]
153. Tan SH, Sapari NS, Miao H, Hartman M, Loh M, **Chng WJ**, Iau P, Buhari SA, Soong R, Lee SC. High-Throughput Mutation Profiling Changes before and 3 Weeks after Chemotherapy in Newly Diagnosed Breast Cancer Patients. *PLOS One* 2015; 10: e0142456. [IF 3.1; Cited 2 times]
154. Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarzer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orłowski RZ, Gillenwater HH, Mohamed N, Feng S, **Chng WJ**; ENDEAVOR investigators. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. *Lancet Oncol* 2016; 17: 27-38. [IF 26.5; Cited 21 times]
155. Kim SJ, Yoon DH, Jaccard A, **Chng WJ**, Lim ST, Hong H, Park Y, Chang KM, Maeda Y, Ishida F, Shin DY, Kim JS, Jeong SH, Yang DH, Jo JC, Lee GW, Choi CW, Lee WS, Chen TY, Kim K, Jung SH, Murayama T, Oki Y, Advani R, d'Amore F, Schmitz N, Suh C, Suzuki R, Kwong YL, Lin TY, Kim WS. A prognostic index for natural killer cell lymphoma after non-

- anthracycline-based treatment: a multicentre, retrospective analysis. *Lancet Oncol.* 2016; 17: 389-400 [IF 26.5; Cited 1 time]
156. **Chng WJ**, Chung TH, Kumar S, Usmani S, Munshi N, Avet-Loiseau H, Goldschmidt H, Durie B, Sonneveld P. Gene signature combinations improve prognostic stratification of multiple myeloma patients. *Leukemia* 2016; 30: 1071-8. [IF 12.1]
  157. Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, Voorhees P, Leleu X, Johnsen HE, Streetly M, Ludwig H, Mellqvist UH, **Chng WJ**, Pilarski L, Einsele H, Hou J, Turesson I, Zamagni E, Chim J, Mazumder A, Westin J, Lu J, Reiman T, Kristinsson S, Joshua D, Roussel M, O'Gorman P, Terpos E, Dimopoulos M, Moreau P, Anderson K, Palumbo A, Kumar S, Rajkumar V, Durie B, Richardson P. Management of relapsed multiple myeloma: Recommendations of the international myeloma working group. *Leukemia* 2016; 30: 1005-17. [IF 12.1; Cited 1 time]
  158. ML Nairismägi, J Tan, JQ Lim, S Nagarajan, CCY Ng, V Rajasegaran, DC Huang, WK Lim, Y Laurensia, GC Wijaya, Z Li, I Cutcutache, WL Pang, S Thangaraju, J Ha, LP Khoo, ST Chin, S Dey, G Poore, L Tan, M Koh, K Sabai, H Rao, KL Chuah, YH Ho, SB Ng, SS Chuang, F Zhang, YH Liu, T Pongpruttipan, YH Ko, PL Cheah, N Karim, **WJ Chng**, TPL Tang, M Tao, K Tay, M Farid, RHH Quek, S Rozen, P Tan, BT Teh, ST Lim, SY Tan, and CK Ong. JAK-STAT and G protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma. *Leukemia* 2016; 30: 1311-1319. [IF 12.1; Cited 3 times]
  159. S Ong, S de Mel, Y Chen, M Ooi, S Surendran, A Lin, LP Koh, YC Linn, A Ho, W Hwang, C Diong, YSM Loh, D Tan, YT Goh, S Gopalakrishnan, and **WJ Chng**. Early Relapse Post Autologous Transplant Is A Stronger Predictor Of Survival Compared To Pretreatment Patient Factors In The Novel Agent Era- Analysis Of Singapore Multiple Myeloma Working Group. *Bone Marrow Transpl* 2016; 51: 933-937. [IF 3.6; Cited 1 time]
  160. M Ooi and **Chng WJ**. Risk Stratification in Multiple Myeloma. *Current Hematologic Malignancy Reports.* 2016; 11: 137-147. [IF 2.1; Cited 1 time]
  161. B Yan, C Ng, G Moshi, K Ban, PL Lee, E Seah, L Chiu, ESC Koay, TC Liu, CH Ng, **WJ Chng**, LP Koh. Myelodysplastic features in a patient with germline CEBPA-mutant acute myeloid leukemia. *J Clin Path* 2016; 69: 652-4. [IF 2.9]
  162. P Sonneveld, H Avet-Loiseau, S Usmani, D Siegel, KC Anderson, **WJ Chng**, P Moreau, M Attal, RA. Kyle, J Caers, J Hillengass, J San Miguel, N van de Donk, H Einsele, J Bladé, BGM Durie, H Goldschmidt, MV Mateos, A Palumbo, R Orłowski. Treatment of Multiple Myeloma with high-risk cytogenetics: A consensus of the International Myeloma Working Group. *Blood* 2016; 127: 2955-62. [IF 11.8; Cited 2 times]
  163. S Kumar, B Paiva, KC Anderson, B Durie, O Landgren, P Moreau, N Munshi, J Blade, MV Mateos, M Dimopoulos, E Kastritis, M Boccadoro, R Orłowski, H Goldschmidt, A Spencer, J Hou, **WJ Chng**, S Usmani, E Zagmani, K Shimizu, S Jagannath, HE Johnsen, E Terpos, A Reiman, RA Kyle, P Sonneveld, PG Richardson, P McCarthy, H Ludwig, W Chen, M Cavo, JL Harousseau, S Lentzsch, J Hillengass, A Palumbo, A Orfao, SV Rajkumar, JS Miguel, H Avet-Loiseau. International Myeloma Working Group Consensus Criteria for Response and Minimal Residual Disease Assessment in Multiple Myeloma. *Lancet Oncol* 2016; 17: E328-346. [IF 26.5]
  164. B Abid, S de Mel, KB Tan, **WJ Chng**. Bortezomib-related Neuropathy masking CNS relapse in Multiple Myeloma; A unique case report and review of the Literature. *Cancer Biol Ther* 2016; 17: 723-6. [IF 2.8]
  165. Mahara S, Lee PL, Feng M, Tergaonkar V, \***Chng WJ**, Yu Q. HIFI- $\alpha$  activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer. *Proc Natl Acad Sci U S A* 2016; 113: E3735-44. [IF 9.4]
  166. Dimopoulos MA, Moreau P, Palumbo A, **Chng WJ**, Feng S. Carfilozomib versus bortezomib for relapsed or refractory myeloma - Authors' reply. *Lancet Oncol.* 2016; 17: e126 [IF 26.5]
  167. B Yan, Y Hu, C Ng, KHK Ban, TW Tan, PT Huan, PL Lee, L Chiu, E Seah, CH Ng, ESC Koay, \***WJ Chng**\*. Coverage analysis in a targeted amplicon-based next generation sequencing panel for myeloid neoplasms. *J Clin Pathol.* 2016; 69: 801-4
  168. V Madan, P Shyamsunder, L Han, MT Anand, Y Nagata, J Sundaresan, D Kanojia, K Yoshida, S Ganesan, N Hattori, N Fulton, KT Tan, T Alpermann, MC Kuo, J Matthews, M Sanada, LZ Liu, Y Shiraishi, S Miyano, E Chendamarai, H Hou, G Malnassy, T Ma, T Bauer, M Garg, LW Ding, QY Sun, W Chien, T Ikezoe, M Lill, A Biondi, M Lübbert, **WJ Chng**, HF Tien, M Heuser, A Ganser, M Koren-Michowitz, SM. Kornblau, HM Kantarjian, D Nowak, WK Hofmann, H Yang, W Stock, A Ghavamzadeh, K Alimoghaddam, T Haferlach, S Ogawa, LY Shih, †V Mathews, †HP Koeffler. Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. *Leukemia* 2016; 30: 1672-1681. [IF 12.1]
  169. J Zhou, S Wang, K Sun and \***WJ Chng**. The emerging roles of exosomes in leukemogenesis. *Oncotarget* 2016; 7: 50698-50707 [IF 5.0].
  170. Yan J, Li B, Lin B, Lee PT, Chung TH, Tan J, Bi C, Lee XT, Selvarajan V, Ng SB, Yang H, Yu Q, \***Chng WJ**. EZH2 phosphorylation by JAK3 mediates a switch to non-canonical function in natural killer/T-cell lymphoma. *Blood* 2016; 128: 948-58. [IF 11.8]

171. Y Chen, M Ooi, A Lin, J Lee, C Nagarajan, CP Diong, YS Lee, NF Grigoropoulos, ZT Lao, S Surendran, EM Teh, YT Goh, **WJ Chng**, SK Gopalakrishnan. Thrombotic microangiopathy during carfilzomib use: case series in Singapore. *Blood Cancer J.* 2016; 6: e450 [IF 4.4]
172. P Moreau, D Joshua, **WJ Chng**, A Palumbo, H Goldschmidt, R Hajek, T Facon, H Ludwig, L Pour, R Niesvizky, A Oriol, L Rosinol, A Suvorov, G Gaidano, T Pika, K Weisel, V Goranova-Marinova, H Gillenwater, N Mohamed, S Aggarwal, S Feng, and MA Dimopoulos. Impact of Prior Treatment on Patients With Relapsed Multiple Myeloma Treated With Carfilzomib and Dexamethasone vs Bortezomib and Dexamethasone in the Phase 3 ENDEAVOR Study. *Leukemia* 2017; 31: 115-122. [IF 12.1]
173. Z Li, Y Xia, LN Feng, JR Chen, HM Li, J Cui, QQ Cai, KS Sim, ML Nairismägi, Y Laurensia, WY Meah, WS Liu, YM Guo, LZ Chen, QS Feng, CP Pang, LJ Chen, SH Chew, RP Ebstein, JN Foo, J Liu, J Ha, LP Khoo, ST Chin, YX Zeng, T Aung, B Chowbay, CP Diong, F Zhang, YH Liu, T Tang, M Tao, R Quek, F Mohamad, SY Tan, BT Teh, SB Ng, **WJ Chng**, CK Ong, Y Okada, S Raychaudhuri, ST Lim, W Tan, RJ Peng, CC Khor, JX Bei. Genetic risk of extranodal natural killer T-cell lymphoma: A genome-wide association study. *Lancet Oncol.* 2016; 17: 1240-7. [IF 26.5]
174. S Mahara, **Chng WJ**, Yu Q. Molecular Switch of EZH2 in hypoxia. *Cell Cycle* 2016; 15: 3007-8. [IF 4.0]
175. PJ Teoh, C Bi, C Sintosebastian, R Fonseca, \***WJ Chng**. Targeting Multiple Myeloma's Vulnerability to Deregulated Protein Homeostasis through the Activation of ER stress via demethylation of TP73 by PRIMA-1. *Oncotarget* 2016; 7: 61806-61819. [IF 5.0]
176. Yang EG, Mustafa N, Tan EC, Poulsen A, Ramanujulu PM, **Chng WJ**, Yen JJ, Dymock BW. Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines. *J Med Chem.* 2016; 59: 8233-62 [IF 5.6]
177. Franke NE, Kaspers GL, Assaraf YG, van Meerloo J, Niewerth D, Kessler FL, Poddighe PJ, Kole J, Smeets SJ, Ylstra B, Bi C, **Chng WJ**, Horton TM, Menezes RX, Musters RJ, Zweegman S, Jansen G, Cloos J. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors. *Oncotarget* 2016; 7: 74779-74796. [IF 5.0]
178. de Mel S, Chen Y, Gopalakrishnan SK, Ooi M, Teo C, Tan D, Teo ML, Tso AC, Lee LK, Nagarajan C, Goh YT, **Chng WJ**. The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma. *Singapore Med J. In Press*
179. Yan B, Chng WJ. Single-cell genomic profiling of acute myeloid leukemia for the clinic: a pilot study. *Oncology Letters. In Press.*
180. Y Li, HS Cheng, **WJ Chng**, V Tergaonkar. Activation of mutant TERT promoter by RAS-ERK signalling is a key step in malignant progression of BRAF-mutant human melanomas. *PNAS* 2016; 113: 14402-14407.
181. S de Mel, J Lee, C Chua, SP Chua, L Gole, LM Poon, J Li, SB Ng, TC Liu, WJ Chng, and YL Chee. Isochromosome 17q; A Novel Finding in Myeloid Sarcoma. *J Clin Exp Hematop* 2016; 130-134.
182. J Hirpara, T Loh, SB Ng, **WJ Chng**, and S Pervaiz. Aberrant Localization of Apoptosis Protease Activating Factor-1 in Lipid Raft Sub-domains of Diffuse Large B Cell Lymphomas. *Oncotarget. In Press*
183. \***WJ Chng**, H Goldschmidt, MA Dimopoulos, P Moreau, D Joshua, A Palumbo, T Facon, H Ludwig, L Pour, R Niesvizky, A Oriol, L Rosinol, A Suvorov, G Gaidano, T Pika, K Weisel, V Goranova-Marinova, HH Gillenwater, N Mohamed, S Feng, S Aggarwal, and R Hájek. Carfilzomib and Dexamethasone vs Bortezomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis From the Phase 3 Study ENDEAVOR. *Leukemia. In Press.*
184. M Tan, I Ng, K Ban, C Ng, L Chiu, E Seah BC Tai, Z Chen, B Yan, CH Ng, \***WJ Chng**. Clinical implications of DNMT3A mutations in a Southeast Asian cohort of acute myeloid leukemia patients. *J Clin Pathol. In Press*
185. Zhou J, Chan ZL, Bi C, Lu X, Chong PS, Chooi JY, Cheong LL, Liu SC, Ching YQ, Zhou Y, Osato M, Tan TZ, Ng CH, Ng SB, Zeng Q, \***Chng WJ**. LIN28B Activation by PRL-3 Promotes Leukemogenesis and a Stem Cell-like Transcriptional Program in AML. *Mol Cancer Res. In Press*
186. V Selvarajan, J Yan, MF Ham, M Salto-Tellez, Dominic, Y Ito, **WJ Chng\***, SB Ng\*. Characterization of the biological and clinical relevance of RUNX3 in Natural Killer/T-Cell lymphoma. *Leukemia. In Press*
187. S Issa, E Braggio, S Molnar, VH Jimenez-Zapeda, S Van Wier, JJ Keats, WM Kuehl, T Price-Troska, GJ Ahmann, KJ Henderson, R Kyle, SV Rajkumar, PR Greipp, D Auclair, J Carpten, A Baker, AK Stewart, PL Bergsagel, **WJ Chng**, R Fonseca. Loss of *TP53* is a predominant prognostic factor in relapsed myeloma and a marker of disease progression. *Submitted*
188. Dong Yin, **WJ Chng**, PH Koeffler. miR-34a functions as a tumor suppressor modulating EGFR through YY1 partially in glioblastoma multiforme. *Submitted*



189. W Zhou, A Tay, J Zhou, N Mustafa, SC Liu, K Jeyaraman, **WJ Chng**, S Shenolikar. Translational repression circumvents Bortezomib resistance in multiple myeloma cells. *Submitted*
190. AR Lam, CX Koo, SWS Ho, YJ Shen, DTC Siang, MSA Karim, **WJ Chng**, S Akira, KJ Ishii & Stephan Gasser. The DNA Sensor ZBP1 Counters ATM-mediated Tumor Suppression of Eμ-Myc-induced B-cell Lymphomagenesis. *Submitted*.
191. S Kumar, JJ Lahuerta, Leleu X, JH Lee, P Moreau, J Hou, R Hajek, P Wu, V Hungria, M Beksac, Knop S, J Lu, W Chen, **WJ Chng**, E Terpos, PG Richardson, A Maiolino, P Sonneveld, I Aydogdu, GJ Morgan, J Li, A Hoering, JF San Miguel, SV Rajkumar, BGM Durie, on Behalf of IMWG. Approaches to Management of Initial Disease Relapse in Multiple Myeloma: In International Myeloma Working Group Study. *Submitted*
192. F Cao, Y Fang, HK Tan, Y Goh, JYH Choy, B Koh, J Tan, N Bertin, A Ramadass, E Hunter, J Green, A Akoulitchev, DG Tenen, W Wang, WJ Chng, MJ Fullwood. Super-Enhancers and Broad H3K4me3 form Complex Gene Regulatory Circuits involving Chromatin Interactions. *Submitted*
193. JG Goh, S Ravikumar, MS Win, Q Cao, AL Tan, JHJ Lim, W Leong, R Herbrecht, PF Troke, **WJ Chng**, MG Netea, YY Dan, BJ Kullberg, LYA Chai. Neutrophils differentially attenuate immune response to Aspergillus infection through complement receptor 3 and induction of myeloperoxidase. *Submitted*
194. CH Ng, C Ng, E Seah, E Fan, G Kam, Z Chen, ESC Koay, **WJ Chng**. Comparing the clinical phenotypes of CALR and JAK2 mutation status in Essential Thrombocytosis – An Asian Perspective. *Submitted*
195. N Mustafa, TH Chung, JXT Lee, CL Bi, H Stefan, P Jonathan, **\*WJ Chng**. VS-5584 mediates potent anti-myeloma activity via the activation of Bim and the upregulation of a class II tumor suppressor gene, RARRES3. *Submitted*
196. H Ludwig, MA Dimopoulos, P Moreau, **WJ Chng**, H Goldschmidt, R Hájek, T Facon, L Pour, R Niesvizky, A Oriol, L Rosiñol, A Suvorov, G Gaidano, T Pika, K Weisel, V Goranova-Marinova, A Palumbo, HH Gillenwater, N Mohamed, S Aggarwal, S Feng, D Joshua. Carfilzomib and Dexamethasone vs Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma: Results of the Phase 3 Study ENDEAVOR (NCT01568866) According to Age Subgroup. *Submitted*
197. D Ho, SR Quake, ERB McCabe, **WJ Chng**, E Chow, X Ding, ML Frisk, B Gelb, G Ginsburg, CM Ho, W Mobley, G Nolan, ST Rosen, P Tan, Y Yun, A Zarrinpar. Engineering Personalized and Precision Medicine. *Submitted*.
198. H Goldschmidt, P Moreau, H Ludwig, R Niesvizky, **WJ Chng**, D Joshua, K Weisel, A Spencer, RZ Orłowski, S Feng, SK Aggarwal, KS Iskander, MA Dimopoulos. Carfilzomib-Dexamethasone vs Subcutaneous or Intravenous Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results From the Phase 3 ENDEAVOR Study. *Submitted*.
199. SB Ng, TH Chung, S Kato, S Nakamura, Emiko Takahashi, YH Ko, JD Khoury, CC Yin, R Soong, AD Jeyasekharan, MM Hoppe, V Selvarajan, SY Tan, ST Lim, CK Ong, ML Nairismägi, P Maheshwari, SN Choo, S Fan, CK Lee, SS Chuang, **\*WJ Chng**. NK/T-cell Lymphoma is molecularly heterogeneous with distinct subtype characterized by nodal presentation and T-cell lineage. *Submitted*
200. Y Zhou, J Zhou, X Lu, TZ Tan, and **\*WJ Chng**. BET Bromodomain Inhibition Promotes De-repression of TXNIP and Activation of ASK1-MAPK Pathway in Acute Myeloid Leukemia. *Submitted*
201. Ng I et al. Clinical implications of a novel 24-bp ZRSR2 deletion identified in acute myeloid leukemia through targeted next-generation sequencing. *Submitted*
202. H Avet-Loiseau, NJ Bahlis, WJ Chng, T Masszi, L Viterbo, L Pour, P Ganly, A Palumbo, M Cavo, C Langer, A Pluta, A Nagler, S Kumar, D Ben-Yehuda, SV Rajkumar, JS Miguel, D Berg, J Lin, H van de Velde, DL Esseltine, A di Bacco, P Moreau, PG Richardson. Efficacy and safety of oral ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma patients: subgroup analysis based on cytogenetic risk of the global, placebo-controlled, phase 3 TOURMALINE-MM1 trial. *In Press*.

\* Corresponding Author

#### **BOOK CHAPTER**

1. **WJ Chng** and PL Bergsagel. "Biology-Based Classification and Staging of Multiple Myeloma." In Myeloma therapy: Pursuing the plasma cell. Ed Sagar Lonial. Humana Press Inc, New Jersey 2008, 41-56.
2. **WJ Chng** and JJ Lu. "Multiple Myeloma and Plasmacytoma". In Radiation Oncology: An Evidence-Based Approach. Ed Jiade Lu and Luther Brady. Springer 2008; 429-444.
3. **WJ Chng** and PL Bergsagel. "Molecular Biology of Multiple Myeloma" In International Haematology Updates: Recent Progress in Multiple Myeloma. Ed Joan Blade. Permanyer Publications, Barcelona, Spain 2008. Pg 1-24.

4. **WJ Chng** and PL Bergsagel. "Molecular Pathogenesis of Multiple Myeloma" In Molecular Haematology. Ed Drew Provan, Wiley-Blackwell Science 2010; 127-139.
5. **WJ Chng**. "Staging and Prognostic Evaluation" In Multiple Myeloma: Status and Development. Ed Chen Wenming, and Wang Xiaojun, People's Military Medical Press 2010; 14-21.
6. **WJ Chng**. "Cytogenetics and Genetics of Myeloma" In Multiple Myeloma: Status and Development. Ed Chen Wenming, and Wang Xiaojun, People's Military Medical Press 2010; 56-65.
7. **WJ Chng** and I Tham. "Multiple Myeloma and Plasmacytoma". In Decision Making in Radiation Oncology Volume 2. Ed Jiade Lu and Luther W Brady. Springer, 2011; 811-832.
8. **WJ Chng**. "Genetic Abnormalities in Multiple Myeloma". In Emerging Cancer Therapeutics: Multiple Myeloma. Ed Shaji Kumar. Demos Medical Publishing, New York 2010; 215-236.
9. Bi CL, **WJ Chng**. "Molecular Genetics of Multiple Myeloma". In Encyclopedia of Life Sciences. Ed David Cooper. John Wiley and Sons, Ltd: Chichester. DOI: 10.1002/9780470015902.a0022446
10. B Yan and **WJ Chng**. "The Role of Centrosomes in Multiple Myeloma". In The Centrosome. Ed Heide Schatten. Humana Press Inc. 2012; 255-276.

#### **PEER-REVIEWED ABSTRACTS**

1. **WJ Chng**, TC Liu. Hepatitis C Screening in Blood Donors – Are We Doing Too Much? Vox Sanguinis 2002; 82 (suppl 2): 52 [Abstract P-154]. (Selected for Poster Presentation)
2. MK Tan, **WJ Chng**, P Kuperan. An Audit of FFP Usage in an Acute General Hospital. Vox Sanguinis 2002; 82 (suppl 2): 201 [Abstract P-601]. (Selected for Poster Presentation)
3. **WJ Chng**, LG Lau, KH Ong, Mow BMF, LK Tan, TC Liu, YK Kueh. Frequent presence of asymptomatic serological immunological abnormalities in certain subtype of patients with myelodysplastic syndromes – Potential therapeutic implication. Blood 2002; 100: 335b [Abstract # 4893].
4. LG Lau, **WJ Chng**, TC Liu, LK Tan, KH Ong, BMF Mow, YK Kueh. 5q- syndrome is distinctly uncommon in a cohort of Asian patients with myelodysplastic syndrome. Blood 2002; 100: 335b [Abstract #4892].
5. **WJ Chng**, CYC Yip, MB Baliwag, TC Liu. Effect of ABO Blood Group on von Willebrand Disease Diagnostic Tests in a Chinese Donor Population. Ann Acad Med Singapore 2003, 32 (suppl): S87 [Abstract I038/MP]. (Selected for Poster Presentation)
6. **WJ Chng**, CF Yim, KS Ng, PY Chong, P Chui, Yow Chan, HC Lai, P Kuperan, D Tai. Venous thromboembolism in intensive care patients with SARS. Ann Acad Med Singapore 2003, 32 (suppl): S97 [Abstract I079/MP]. (Selected for Poster Presentation)
7. MK Ang, C Sum, **WJ Chng**, P Kuperan. D-Dimer: A simple and useful test for exclusion of clinically suspected deep vein thrombosis. Ann Acad Med Singapore 2003, 32 (suppl): S105 [Abstract I111/PD]. (Selected for Poster Presentation)
8. **WJ Chng**, HC Lai, A Earnest, P Kuperan. Changes in haematological parameters in Severe Acute Respiratory Syndrome. Ann Acad Med Singapore 2003, 32 (suppl): S150 [Abstract II065/MP]. (Selected for Poster Presentation)
9. **WJ Chng**, Sum C, Kuperan P. Causes of isolated prolonged activated partial thromboplastin time (APTT) in an acute general hospital: A guide to fresh frozen plasma (FFP) usage. Ann Acad Med Singapore 2004; 33(suppl): S72-S73. (Selected for Poster Presentation - Best poster Finalist, NHG Congress 2004)
10. **WJ Chng**, Lai HC, Shen L, Kuperan P. Comparison between haematological parameters in severe respiratory syndrome and dengue fever. Ann Acad Med Singapore 2004; 33(suppl): S12-S13. (Selected for Oral Presentation - NHG Doctor Award Finalist, NHG Congress 2004)
11. Lau LG, **WJ Chng**, Yusof NM, Ong KH, Tan LK, Mow BMF, Koay ESC, Liu TC and Kueh YK. Flt3-activating mutations are distinctly rare and do not appear to have prognostic significance in a local cohort of patients with myeloid malignancies. Ann Acad Med Singapore 2004, 33(suppl): S112 [abstract I088/MPL]. (Selected for Poster Presentation)
12. Lau LG, **WJ Chng**, Yusof NM, Ong KH, Tan LK, Mow BMF, Koay ESC, Liu TC and Kueh YK. Prognostic factors in patients with acute myeloid leukaemias and high-grade myelodysplastic syndromes – A single institution evaluation. Ann Acad Med Singapore 2004, 33(suppl): S103 [abstract I050/MPC]. (Selected for Poster Presentation)
13. **WJ Chng**, JM Winkler, SA Van Wier, et al. Fluorescent in situ hybridization based trisomy index identifies hyperdiploid monoclonal gammopathy of undetermined significance. Haematologica/The haematology journal 2005; 90(s1): 74 [abstract PO.112]. (Selected for Poster Presentation)
14. Fonseca R, Van Wier S, **Chng WJ**, et al. Low level amplification (duplication) of 1q21 in myeloma and prognosis; the role of CKS1B. Blood 2005; [abstract 624]. (Selected for Oral Presentation – RF)
15. Kumar S, Greipp PR, Haug J, Kline M, Blood E, **Chng WJ**, et al Comparison of myeloma cell gene expression profiles pre and post thalidomide-dexamethason therapy provides insight into potential mechanisms. Blood 2005; [abstract 3480]. (Selected for Oral Presentation – SK)

16. Mulligan G, Mitsiades C, Bryant B, Zhan F, **Chng WJ**, et al. Pharmacogenomics (PGx) research in the APEX randomised multicenter interational phase 3 trial comparing bortezomib and high-dose dexamethasone (Dex) Blood 2005; [abstract 3491]. (Selected for Poster Presentation)
17. **Chng WJ**, Van Wier SA, Ahmann GJ, et al. Genomic analysis of high hyperdiploid acute lymphoblastic leukemia and hyperdiploid multiple myeloma suggests differential gene dosage effect on expression and provide clues to preferential selection of recurrently trisomic chromosomes. Blood 2005; [abstract 3006]. (Selected for Poster Presentation)
18. **Chng WJ**, Gonzalez-Paz N, Kumar S, et al. Cancer/Testis antigen profiling in multiple myeloma define a cohort of patients with poor prognosis regardless of genetic subtypes. Blood 2005; [abstract 3381]. (Selected for Poster Presentation)
19. **Chng WJ**, Gonzalez-Paz N, Kumar S, et al. Gene expression profiling identifies 4 sub-classes of hyperdiploid myeloma with distinct clinical associations. Blood 2005; [Abstract 1537]. (Selected for Poster Presentation)
20. **Chng WJ**, Van Wier SA, Ahmann GJ, et al. Gene expression profiling of hyperdiploid myeloma reveal complex gene dosage effects and an mRNA translation/protein biosynthesis signature. Blood 2005; [abstract 1538]. (Selected for Poster Presentation)
21. **Chng WJ**, Van Wier SA, Ahmann GJ, et al. Compendium of karyotypic abnormalities and their clinical implications in hyperdiploid multiple myeloma. Blood 2005; [abstract 1539]. (Selected for Poster Presentation)
22. Van Wier SA, **Chng WJ**, Ahmann GJ, et al. One half of patients with Waldenstrom Macroglobulinemia have large deletions of chromosome 6q. Blood 2005; [abstract 1546]. (Selected for Poster Presentation)
23. Kumar S, Greipp PR, Haug JL, Kline M, **Chng WJ**, et al. Comparison of newly diagnosed and relapsed refractory multiple myeloma using transcriptional profiling of myeloma cells. Blood 2005; [abstract 1555]. (Selected for Poster Presentation)
24. Kumar S, Greipp PR, Haug J, Kline M, **Chng WJ**, et al. Gene expression profiling of myeloma cells at diagnosis can predict response to therapy with thalidomide and dexamethasone combination. Blood 2005; [abstract 508]. (Selected for Poster Presentation)
25. Gonzalez-Paz N, **Chng WJ**, Kumar S, et al. Significance of the tumor suppressor p53 codon 72 polymorphic variants in multiple myeloma. Blood 2005; [abstract 5102]
26. **Chng WJ**, Greg Ahmann, Kim Henderson, et al. Clinical implications and possible mechanisms of centrosome amplification in plasma cell neoplasm. Proceeding AACR Annual Meeting 2006 [abstract 1147]. (Selected for Poster Presentation)
27. **Chng WJ**, Price-Troska T, Van Wier S, et al. Clinical and biological implications of defective p53 pathway in multiple myeloma. J Clin Oncol 2006 ASCO Ann Mtg Proceed Part I, Vol 24: 18S (June 20 Suppl): 17516 [abstract 17516]
28. **Chng WJ**, et al. Combined high resolution array comparative genomic hybridization and gene expression profiling reveal RB1 haploinsufficiency as a possible tumorigenic mechanism in myeloma. Blood 2006; [abstract 113]. (**Selected for oral presentation – CWJ**)
29. **Chng WJ**, et al. Survival of genetic subtypes of relapsed myeloma may be modulated by secondary events. Blood 2006; [abstract 132]. (**Selected for oral presentation – CWJ**)
30. **Chng WJ**, et al. A gene expression based centrosome index is a powerful prognostic factor in myeloma. Blood 2006; [abstract 3388]. (Selected for poster presentation).
31. Bergsagel PL, Carpten J, Chesi M,.....**Chng WJ**, et al. Promiscuous mutations frequently activate the non-canonical NFKB pathway in multiple myeloma. Blood 2006; [Abstract 109]. (**Selected for oral presentation – PLB**)
32. Tiedemann RE, Gonzalez-Paz N, Santana-Davila R, **Chng WJ**, et al. Natural history, genetic aberrations and survival distinguish primary plasma cell leukemia from multiple myeloma with leukemic transformation. Blood 2006; [abstract 3587]. (Selected for poster presentation)
33. Schop RFJ, Mancini C, **Chng WJ**, et al. High density oligoneucleotide array CGH analysis of CLL reveals areas of recurrent genomic gain or loss. Blood 2006; [abstract 2093]. (Selected for poster presentation)
34. Baker AS, **Chng WJ**, Keats JJ, et al. Using array-based comparative genomic hybridization (aCGH) to identify candidate tumor suppressor genes in multiple myeloma. In: American Association of Cancer Research Annual Meeting: Proceedings; 2007 Apr 14-18; Los Angeles, CA. Philadelphia (PA): AACR; 2007. [Abstract 2936]. (Selected for Poster Presentation)
35. **Chng WJ**, JJ Keats, M Chesi, et al. Prediction of response to bortezomib and dexamethasone resistance in myeloma by novel mutations in the NFKB pathway. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I; 25(18S): 442S [Abstract 8007]. (**Selected for oral presentation – CWJ**).
36. Bergsagel PL, Chesi M, Keats J, **Chng WJ** et al. Molecular principles underlying myeloma. Haematologica/Haem J 2007; 92(S2): 1 [Abstract S1.1]. (Plenary Session – PLB)
37. Keats JJ, **Chng WJ**, Braggio E, et al. High resolution mapping of common gains and losses in myeloma. Haematologica/Haem J 2007; 92(S2): 64 [Abstract S11.1]. (**Selected for oral presentation – JJK**)
38. Henry T, **Chng WJ**, Baker A, et al. Pathogenesis of RB1 haploinsufficiency in deletion 13 myeloma. Haematologica/Haem J 2007; 92(S2): 98 [Abstract PO-105]. (Selected for poster presentation – TH)

39. Sebag M, Stewart AK, **Chng WJ**, et al. Mutually exclusive activation of NFkB or STAT3 signaling pathways in multiple myeloma. *Haematologica/Haem J* 2007; 92(S2): 98 [Abstract PO-107]. (Selected for poster presentation – MS).
40. Van Wier SA, Larson D, **Chng WJ**, et al. Genomic aberrations in monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) and the risk of progression to multiple myeloma (MM). *Haematologica/Haem J* 2007; 92(S2): 99 [Abstract PO-109]. (Selected for poster presentation – SAV).
41. Keats JJ, Tiedemann R, Van Wier S, Schop R, Baker A, **Chng WJ**, et al TRAF3 is a novel tumor suppressor that is frequently inactivated in myeloma. *Haematologica/Haem J* 2007; 92(S2): 106 [Abstract PO-134]. (Selected for poster presentation – JJK).
42. Ahmann GJ, Henderson KJ, Price-Troska TL, **Chng WJ**, et al. Assessing the purity, sensitivity and specificity of two plasma cell selection methods. *Haematologica/Haem J* 2007; 92(S2): 107 [Abstract PO-138]. (Selected for poster presentation – GJA),
43. **Chng WJ**, Keats JJ, Bergsagel PL, Fonseca R. Disease stage, sample purity and impact on gene expression profiling (GEP) studies in plasma cell proliferative disease (PPD). *Haematologica/Haem J* 2007; 92(S2): 108 [Abstract PO-139]. (Selected for poster presentation – CWJ),
44. **Chng WJ**, Kuehl WM, Bergsagel PL. Synthesis of genetic and molecular prognostic models in myeloma (MM). *Haematologica/Haem J* 2007; 92(S2): 110 [Abstract PO-148]. (Selected for poster presentation – CWJ).
45. **Chng WJ**, Chesi M, Price-Troska T, et al. Activation of MYC pathway is a unifying pathological event in the progression from Monoclonal gammopathy of undetermined significance (MGUS) to myeloma (MM). *Blood* 2007; 100 [Abstract 241]. (**Selected for oral presentation – CWJ**)
46. **Chng WJ**, Fonseca R, Bergsagel PL, et al. Gene expression profiling of pulmonary Mucosa-associated lymphoid tissue (MALT) lymphoma identifies new diagnostic markers, biological heterogeneity and therapeutic targets. *Blood* 2007; 110 [Abstract 560]. (**Selected for oral presentation – CWJ**)
47. **Chng WJ**, Chung TH, Keats JJ et al. Identification of survival critical genomics gains or losses in myeloma (MM) using array-comparative genomic hybridization (aCGH). *Blood* 2007; 110 [Abstract 2471]. (Selected for poster presentation – CWJ)
48. **Chng WJ**, Keats JJ, Braggio E et al. Multiple myeloma (MM) is characterized by genomic instability regardless of ploidy categories and degree of karyotypic complexity is an important prognostic factor. *Blood* 2007; 110 [Abstract 1476]. (Selected for poster presentation – CWJ)
49. Mulligan G, Bryant B, Roels S.....**Chng WJ** et al. Pharmacogenomics study of biological pathways related to Bortezomib activity in myeloma. *Blood* 2007; 110 [Abstract 392]. (**Selected for oral presentation – GM**)
50. Sebag M, Stewart K.....**Chng WJ** et al. PRL3 is a modulator of IL6/STAT3 signaling and defines a population of multiple myeloma patients distinct from those that activate NFkB. *Blood* 2007; 110 [Abstract 671]. (**Selected for oral presentation – MS**)
51. Keats JJ, Chapman M.....**Chng WJ** et al. Genome-wide profiling of gene expression and DNA copy number alterations in multiple myeloma. *Blood* 2007; 110 [Abstract 396]. (**Selected for oral presentation – JJK**)
52. Zhu YX, Shi CX, Lian SBL, **Chng WJ**, Trudel S, Stewart K. Identification of Vacuolar H<sup>+</sup>-ATPase as a therapeutic target for myeloma therapeutics. *Blood* 2007; 110 [Abstract 257]. (**Selected for oral presentation – ZYX**)
53. Jimenez-Zepeda VH, **Chng WJ**, Fonseca R. Dissecting karyotypic patterns in non-hyperdiploid multiple myeloma. *Blood* 2007; 110 [Abstract 2491]. (Selected for poster presentation – VHJZ)
54. Jimenez-Zepeda VH, **Chng WJ**, Fonseca R. Waldenstrom Macroglobulinemia: The impact of cytogenetic analysis. *Blood* 2007; 110 [Abstract 2490]. (Selected for poster presentation – VHJZ)
55. Zhu YX, Yin H, Que Q,...**Chng WJ** et al. RNAi screen of the druggable genome to identify modulators of Bortezomib in myeloma. *Blood* 2007; 110 [Abstract 2478]. (Selected for poster presentation – ZYX)
56. Henry TJ, **Chng WJ**, Carpten J, et al. RB1 haploinsufficiency confers a proliferation advantage in myeloma cell lines. *Blood* 2007; 110 [Abstract 2489]. (Selected for poster presentation – TH)
57. Braggio E, Keats JJ, **Chng WJ**, et al. Comparative high resolution array-based CGH (aCGH) in B-cell malignancies. *Blood* 2007; 110 [Abstract 2479]. (Selected for poster presentation – EB)
58. Danae H, Bryant B, Roels S,...**Chng WJ**, et al. High-resolution assessment of gains and losses of chromosomes in patients with multiple myeloma treated with bortezomib.. *Blood* 2007; 110 [Abstract].
59. Molnar S, ..... **Chng WJ**, et al. Loss of p53 is a marker of progression in plasma cell neoplasias and is a negative prognostic factor in relapsed disease. *Blood* 2008; [abstract]. (Selected for poster presentation – MS).
60. Ngo HT,..... **Chng WJ**, et al. Proteomic Analysis of multiple myeloma identifies upregulation of CR1K protein, a novel protein regulating migration and adhesion. *Blood* 2008; [abstract]. (Selected for Oral presentation – NHT).
61. Zhou JB,..... **Chng WJ**, et al. Identification of core gene signature associated with synergism between ABT-869, a FLT-3 inhibitor and SAHA, a HDAC inhibitor in AML with FLT-3 ITD mutation. *Blood* 2008; [abstract]. (Selected for poster presentation – ZJB).

62. Braggio E, Remstein E, **Chng WJ**, et al. High resolution array-based analysis in marginal zone lymphomas and lymphoplasmacytic lymphomas identified disease specific patterns of chromosome abnormalities. *Blood* 2008; [abstract] (Selected for oral presentation – EB).
63. **Chng WJ**, et al. Genomic complexity and recurrent aberration in multiple myeloma: analysis of a compendium of aCGH and gene expression profiles. *Blood* 2008; [abstract]. (Selected for poster presentation – CWJ).
64. **Chng WJ**, et al. Identification of Cellular Pathways Mediating progression of monoclonal gammopathy (MGUS) to multiple myeloma (MM) using gene expression profiling (GEP). *Blood* 2008; [abstract]. (Selected for poster presentation – CWJ).
65. **Chng WJ**, et al. Gene expression profiling of post-follicular B-cell lymphoma. *Blood* 2008; [abstract]. (Selected for oral presentation – CWJ)
66. Tuchman SA, **Chng WJ**, Anguiano A et al. *JCO* 2009; 27:15s [abstract 8521]. (Selected for oral presentation – TSA)
67. **Chng WJ**, et al. MYC Activation is a common transformation event in myeloma and associated with poor prognosis. *Blood* 2009; 114: 344 [abstract 834]. (Selected for oral presentation - CWJ)
68. **Chng WJ**, et al. Gene expression profiling reveals activation of multiple oncogenic pathways and over-expression of survivin in the pathogenesis of extranodal Nasal-type NK/T cell lymphoma. *Blood* 2009; 114: 1511 [abstract 3931]. (Selected for poster presentation)
69. Xie Z, Bi C, Cheong LL, ..... **Chng WJ**. Suppression of Alox5 gene is involved in DZNep induced apoptosis in multiple myeloma cells. *Cancer Res* 2010 (Selected for poster presentation)
70. **Chng WJ**, et al. A MYC activation signature is common in multiple myeloma and associated with shorter survival that can be overcome by velcade. *Haematologica* 2010; 95: 158 [Abstract 391] (Selected for poster presentation)
71. Braggio E, Dogan A, **Chng WJ**, et al. Dissecting the genetic basis of marginal zone lymphoma reveals a predilection for NF-KB activation by clonal MZL located at extranodal sites. *Blood* 2010; 116: 1692 [Abstract 4160] (Selected for poster presentation)
72. Xie Z, Gunaratne J, Huang G, Blackstock W, **Chng WJ**. Plasma membrane proteomics identifies biomarkers associated with t(4;14) multiple myeloma. *Haematologica* 2011; 96 (Suppl 1): S40 [Abstract 31] (Selected for Poster Presentation at International Myeloma Workshop, Paris 2011)
73. Reghunathan R, Bi C, Huang G, **Chng WJ**. Differential gene expression profiling of clonogenic multiple myeloma cells reveals signatures of proliferation and differentiation. *Haematologica* 2011; 96 (Suppl 1): S43 [Abstract 40] (Selected for Poster Presentation at International Myeloma Workshop, Paris 2011)
74. Tan D, Loh Y, Diong C, Poon M, Linn YC, Tan LP, Goh YT, Koh LP, Hwang W, **Chng WJ**. An abnormal non-hyperdiploid karyotype, in multiple myeloma predicts for an adverse outcome after high dose therapy with autologous stem cell transplantation. *Haematologica* 2011; 96(s2): 122 [abstract 296]. (Selected for poster presentation at the European Haematology Association, London 2011)
75. D. C. Tan, K. H. Ong, L. P. Koh, S. S. Wong, M. T. Khin, L. H. Lee, Y. T. Goh, **W. J. Chng**. The impact of frontline risk-adapted strategy on the overall survival (OS) of patients with newly diagnosed multiple myeloma (MM): A population study in Singapore (SG). *J Clin Oncol* 29: 2011 [suppl; abstr 8081]. (Selected for poster presentation at the American Society of Clinical Oncology, Chicago, USA 2011)
76. Feldman AL, Huang G, Porcher JC, Kip S, Ansell SM, Dogan A, **Chng WJ**. ALK-Negative Anaplastic Large Cell Lymphomas with 6p25.3 Translocations Show a Histone Modifying Gene Expression Signature. *Blood* 2011 [Abstract 88]. (Selected for oral presentation)
77. Hu S, Mirshahidi S, Bi C, **Chng WJ**, Hsu HW, Wu SY, Pan J, Cen JN, Chen CS. C3aR1 Contributed to Acute Myeloid Leukemia Acquired Resistance to ABT-737 and Involved in the Process of AML. *Blood* 2011 [Abstract 1435]. (Selected for poster presentation)
78. Zhou J, Cheong LL, Mahara S, Liu SC, Chong PS, Bi C, Koh TL, Ong KO, Zeng Q, **Chng WJ**. The Pro-Metastasis Tyrosine Phosphatase, PRL-3 (PTP4A3), is a Novel Target of BCR-ABL Signaling Involved in Human Chronic Myeloid Leukemia. *Blood* 2011 [Abstract 2741]. (Selected for poster presentation)
79. Hillmer AM, Ng KP, Chuah C, Juan WC, Ko TK, Teo ASM, Ariyaratne PN, Takajashi N, Sawada K, Fei Y, Lee WH, Huang W, Allen JC, Woo XY, Nagarajan N, Kumar V, Thalamuthu A, Poh WT, Ang AL, Mya HT, How GF, Yang LY, Koh LP, Nadarajan V, **Chng WJ**, Than H, Lim LC, Goh YT, Nothen MM, Wong TY, Shahab A, Ruan X, Cacheux-Rataboul V, Sung WK, Ruan Y, Ong ST. A Common Deletion Polymorphism in the BIM Gene Contributed to Intrinsic Imatinib Resistance in Chronic Myelogenous Leukemia. *Blood* 2011 [Abstract 1666] (Selected for poster presentation)
80. Chung TH, Fonseca R, **Chng WJ**. A Novel Measure of Chromosome Instability is an Independent Prognostic Factor in Multiple Myeloma. *Blood* 2011 [Abstract 1824](Selected for poster presentation)
81. **Chng WJ**, Yan J, Huang G, Selvarajan V, Tay J, Lin B, Bi C, Tan J, Ng SB. Dysregulated MicroRNA Affects Pathways and Targets of Biological Relevance in Nasal-Type Natural Killer / T-cell Lymphoma. *Blood* 2011 [Abstract 2637] (Selected for Poster Presentation).

82. Brian G. Durie, Philippe Moreau, Pieter Sonneveld, Gareth J Morgan, Juan José Lahuerta, Meral Bekzac, Evangelos Terpos, Roman Hajek, Vânia Tietsche de Moraes Hungria, Angelo Maiolino, **Wee Joo Chng**, Jae Hoon Lee, Hou Jian, Paul Gerard Guy Richardson, Wenming Chen, Stefan Knop, Antje Hoerring, Xavier Leleu, Jesús F. San-Miguel, Shaji Kumar, International Myeloma Working Group. Regional differences in the treatment approaches for relapsed multiple myeloma: An IMF study. ASCO Annual Meeting Proceedings 2012, Vol. 30: 533s [Abstract 8095] (Selected for poster presentation)
83. Jae Hoon Lee, Kihyun Kim, Jin Seok Kim, Chang Ki Min, Kazuyuki Shimizu, Takaaki Chou, Hiroshi Kosugi, Kenshi Suzuki, Hiroyuki Hata, Wenming Chen, Jian Hou, Shang-Yi Huang, **Wee Joo Chng**, Daryl C.L. Tan, Gerrard Teoh, James Chim, Raymond Liang, Weerasak Nawarawong, Noppadol Siritanaratkul, Brian G. Durie. Clinical profile of multiple myeloma in Asia: An Asian Myeloma Network (AMN) study. ASCO Annual Meeting Proceedings 2012, Vol. 30: 533s [Abstract 8097] (Selected for poster presentation)
84. Shaji K. Kumar, Betsy R. LaPlant, **Wee Joo Chng**, Jeffrey A. Zonder, Natalie Callander, Vivek Roy, Briant Furth, Charles Erlichman and Keith Stewart. Phase 1/2 Trial of a Novel CDK Inhibitor Dinaciclib (SCH727965) in Patients with Relapsed Multiple Myeloma Demonstrates Encouraging Single Agent Activity. Blood 2012 [Abstract 76] (**Selected for oral presentation**)
85. **Wee-Joo Chng**, Junli Yan, Siok-Bian Ng, Jim Tay, Baohong Lin, Tze-Loong Koh, Joy Tan, Viknesvaran Selvarajan, Shaw-Cheng Liu, Chonglei Bi, Gaofeng Huang and Qiang Yu. EZH2 Is Aberrantly Expressed and Plays a Pro-Proliferative Role Independent of Its Methyltransferase Activity in Natural Killer / T-Cell Lymphoma. Blood 2012 [Abstract 3498] (Selected for poster presentation).
86. Zhigang Xie, Jayantha Gunaratne, Lip Lee Cheong, Shaw Cheng Liu, Tze Loong Koh, Gaofeng Huang, Walter Blackstock and **Wee-Joo Chng**. Plasma Membrane Proteomics Identifies Biomarkers Associated with T(4;14) Multiple Myeloma. Blood 2012 [Abstract 1314] (Selected for poster presentation).
87. C Bi, J Zhou, TH Chung, G Huang, J Yan, **WJ Chng**. Identification of tumor suppressive microRNAs in Multiple Myeloma by Pharmacologic Unmasking. Clinical lymphoma, myeloma and leukemia 2013; 13 (suppl 1): S37 [abstract O-2] (Selected for plenary oral presentation, winner of travel award)
88. Z Xie, C Bi, **WJ Chng**. MMSET knockdown induced apoptosis in t(4;14) multiple myeloma cells through regulating IRF4 expression. Clinical lymphoma, myeloma and leukemia 2013; 13 (suppl 1): S59 [abstract P-29] (Selected for poster presentation)
89. Chong SYP, Zhou J, Cheong LL, Guo T, Kwan SS, Zeng Q, **Chng WJ**. Global discovery of dysregulated protein expression and phosphorylation networks identifies Leo1 as a key substrate of PRL-3 phosphatase (PTP4A3) in leukemogenesis. AACR 2013 [Abstract 1108] (selected for oral presentation)
90. Teoh PJ, Yan J, **Chng WJ**. Genomic and functional characterization identifies different manifestations of p53 pathway in 17p13 deletion cases of multiple myeloma. AACR 2013 [abstract 786] (selected for Poster Presentation)
91. Nurulhuda Mustafa, Stefan Hart, **Wee Joo Chng**. A Novel and Highly Selective Dual PI3K/mTOR Kinase Inhibitor VS-5584. Shows Promising Therapeutic Potential For The Treatment Of Multiple Myeloma. ASH 2013 [Abstract 4433] (Selected for Poster Presentation)
92. Tze Loong Koh, **Wee Joo Chng**. EZH2 Mediates Resistance To Apoptosis In Nk1l By Activating Nfkb Signaling Through Repression Of TNFAIP3/A20 By H3K27 Trimethylation. ASH 2013 [Abstract 1278] (Selected for Poster Presentation)
93. Neeraj Gupta, Yeow Tee Goh, Chang-ki Min, Jae Hoon Lee, Cheolwon Suh, Kihyun Kim, Raymond Wong, James Chim, Michael J. Hanley, Huyuan Yang, Karthik Venkatakrishnan, Ai-Min Hui, Claudia Schusterbauer, **Wee Joo Chng**. Phase 1 pharmacokinetic (pk) study of ixazomib citrate (mln9708) plus lenalidomide and dexamethasone in asian patients (pts) with relapsed/refractory multiple myeloma (rrmm). EHA 2014 [Abstract 4477] (selected for poster presentation)
94. Joanne Lee Shu Xian, Baohong Lin, **Wee Joo Chng**. Investigating the prognostic significance of miRNA-335 expression in adult acute lymphoblastic leukemia. EHA 2015 [Abstract E872] (selected for e-poster)
95. SJ Kim.....**Wee Joo Chng**.....Kim WS. International Extranodal NK/T-cell lymphoma project: prognostic factors in the era of nonanthracycline-based treatment. EHA 2015 [Abstract S110] (**Selected for Oral Presentation**)
96. M Dimopoulos.....**Wee Joo Chng**. Carfilzomib and dexamethasone improves progression free survival and response rates versus bortezomib and dexamethasone in patients with relapsed multiple myeloma: The phase 3 study Endeavour. EHA 2015 [abstract LB2071] (**selected for oral presentation** as late breaking abstract)
97. Zhou JB.....**Wee Joo Chng**. Pro-metastasis phosphatase PRL-3 transforms leukemia stem cells and promotes leukemogenesis in AML via activation of SOX4/LIN28B/Let-7 signaling. EHA 2015 [abstract P549] (Selected for Poster Presentation)
98. Xie Z and **WJ Chng**. MMSET I act as an oncogene in t(4;14) multiple myeloma cells. International Myeloma Workshop 2015. [Abstract PO-236] (Invited poster Presentation)

99. N Mustafa, TH Chung, EM Grosslinger, H Wulff, GK Chandy and **WJ Chng**. The KCa2.3 potassium channel at 1q21 is associated with disease progression and reduced survival during relapse in multiple myeloma. International Myeloma Workshop 2015. [Abstract PO-251] (Invited poster Presentation)
100. PL Lee, B Yan, CH Ng, KHK Ban, **WJ Chng** and ESC Koay. Characterization of AML Patients with CEBPA Mutations in a South-East Asian Population. ASH 2015 [Abstract 2574] (Selected for Poster Presentation)
101. TK Ko, XXS Soh, W Yu, PS. Winter, T Pathiraja, A Javed, S Malik, JHJ Tan, C Chuah, N Takahashi, R Bhatia, **WJ Chng**, P Valent, S Cerny-Reiterer, KP Ng, C Tennakoon, Q Hoi, P Guan, ASM Teo, WH Lee, P Tan, WK Sung, P Ng, A Hillmer, KC Wood, S Rozen, and ST Ong. Functional Analysis of the CML Blast Crisis Transcriptome and Epigenome Using Crispr-CAS9 and Pharmacologic Approaches. ASH 2015 [Abstract 2764] (Invited poster presentation)
102. SD Russell, A Lyon, DJ Lenihan, P Moreau, D Joshua, **WJ Chng**, A Palumbo, H Goldschmidt, R Hájek, T Facon, H Ludwig, L Pour, R Niesvizky, A Oriol, L Rosiñol, A Suvorov, G Gaidano, V Goranova-Marinova, HH Gillenwater, N Mohamed, S Feng and MA Dimopoulos. Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866). ASH 2015 [Abstract 4250] (invited poster presentation)
103. ST Ong, T Pathiraja, A Javed, XXS Soh, S Malik, JHJ Tan, TK Ko, C Chuah, N Takahashi, R Bhatia, KP Ng, WJ Chng, C Tennakoon, Q Hoi, P Guan, ASM Teo, WH Lee, P Tan, WK Sung, P Ng and A Hillmer. The Genomic and Epigenomic Landscapes of Blast Crisis Transformation in Chronic Myeloid Leukemia. ASH 2015 [Abstract 3737] (Invited Poster Presentation)
104. SK Kumar, JH Lee, MA Dimopoulos, E Terpos, E Kastritis, WJ Chng, AJ Jurczyszyn, H Handa, S Ozaki, X Leleu, P Moreau, JJ Lahuerta, C Shustik, DD Waller, M Beksac, R Vij, MD, K Kim, JS Kim, AZ Badros, Me Alsina and BGM Durie. Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study. ASH 2015. [Abstract 4201] (Invited Poster Presentation)
105. Antonio Palumbo, Meletios A. Dimopoulos, Philippe Moreau, Wee-Joo Chng, Hartmut Goldschmidt, Roman Hájek, Thierry Facon, Heinz Ludwig, Ludek Pour, Ruben Niesvizky, Albert Oriol, Laura Rosiñol\*, Aleksandr Suvorov\*, Gianluca Gaidano, Tomas Pika\*, Katja Weisel\*, Vesselina Goranova-Marinova\*, Heidi H. Gillenwater, Nehal Mohamed\*, Shibao Feng\* and D Joshua. Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Results of the Phase 3 Study Endeavor (NCT01568866) According to Age Subgroup. Ash 2015 [Abstract 1844] (Invited Poster Presentation)
106. Philippe Moreau, Douglas Joshua, Wee-Joo Chng, Antonio Palumbo, Hartmut Goldschmidt, Roman Hájek, Thierry Facon, Heinz Ludwig, Ludek Pour, MD, Ruben Niesvizky, Albert Oriol, MD, Laura Rosiñol, Aleksandr Suvorov, Gianluca Gaidano, Tomas Pika, Katja Weisel, Vesselina Goranova-Marinova, Heidi H. Gillenwater, Nehal Mohamed, Shibao Feng and Meletios Dimopoulos. Impact of Prior Treatment on Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in a Subgroup Analysis of the Phase 3 Endeavor Study (NCT01568866). ASH 2015 [Abstract 729] (Invited Oral Presentation)
107. Wee-Joo Chng, Hartmut Goldschmidt, Meletios A. Dimopoulos, Philippe Moreau, Douglas Joshua, Antonio Palumbo, Thierry Facon, Heinz Ludwig, Ludek Pour, Ruben Niesvizky, Albert Oriol, Laura Rosinol, Aleksandr Suvorov, Gianluca Gaidano, Tomas Pika, Katja Weisel, Vesselina Goranova-Marinova, Heidi H. Gillenwater, Nehal Mohamed, Shibao Feng and Roman Hájek. Efficacy and Safety of Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Endeavor (NCT01568866). ASH 2015. [Abstract 30] (Invited Oral Presentation)
108. Niels Franke, Gertjan J.L. Kaspers, Yehuda G Assaraf, Johan Van Meerloo, Denise Niewerth, Terzah M. Horton, Wee Joo Chng, Chonglei Bi, Rene X. Menezes, Renée J. Musters, Pino J. Poddighe, Floortje Kessler, Serge Smeets, Bauke Ylstra, Sonja Zweegman, Gerrit Jansen and Jacqueline Cloos. Marcks Marks Resistance to Proteasome Inhibitors: Exocytosis of Polyubiquitinated Proteins in Bortezomib-Resistant Leukemia Cells. ASH 2015 [Abstract 3712] (Invited Poster Presentation)
109. Sanjay De Mel, Yunxin Chen, Adeline Lin, Eng Soo Yap, Teck Guan Soh, Joanna Mah, Melissa G. Ooi, Sathish Kumar Gopalakrishnan, Lara Kristina Sioco Donato, Nurul Aidah Abdul Halim, Wee-Joo Chng and lip Kun Tan. Vinorelbine-Cyclophosphamide Compared to Cyclophosphamide in Peripheral Blood Stem Cell Mobilization for Multiple Myeloma. ASH 2015 [Abstract 3103] (Invited poster presentation)
110. Boheng Li, Junli Yan, Tae-Hoon Chung, Pei Tsung Lee and Wee-Joo Chng. Mapping the Functional Cofactors of Oncogenic EZH2 in Natural Killer / T-cell Lymphoma. ASH 2016 [Abstract 1773] (Invited poster presentation).
111. Shaji Kumar, Meletios Dimopoulos, Efstathios Kastritis, Evangelos Terpos, Hareth Nahi, Hartmut Goldschmidt, Jens Hillengass, Xavier Leleu, Meral Beksac, Melissa Alsina, Albert Oriol, Michele Cavo, Enrique M. Ocio, Maria Victoria Mateos, Elizabeth K. O'Donnell, Ravi Vij, Henk M.

- Lokhorst, Niels W.C.J. van de Donk, Chang-Ki Min, Tomer Mark, Ingemar Turesson, Markus Hansson, Heinz Ludwig, Sundar Jagannath, Michel Delforge, Charalampia Kyriakou, Parameswaran Hari, Ulf-Henrik Mellqvist, Saad Z Usmani, Dominik Dytfeld, Ashraf Z Badros, Philippe Moreau, Kihyun Kim, Paula Rodriguez Otero, Jae Hoon Lee, Chaim Shustik, Daniel Waller, Wee Joo Chng, Shuji Ozaki, Je-Jung Lee, Javier de la Rubia, Hyeon Seok Eom, Laura Rosinol, Juan José Lahuerta, Anna Sureda, Jin Seok Kim, and Brian G.M. Durie. Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study. ASH 2016 [Abstract 4414] (Invited poster presentation).
112. Wee J Chng, Kihyun Kim, Jeffrey Huang, Chor Sang Chim, Hiroshi Kosugi, Naoki Takezako, Junichi Sakamoto, Sathish Kumar Gopalakrishnan, Yuan Wei, Ling Ying Zhuo, Je-Jung Lee, Sung-Soo Yoon, Jin Seok Kim, Chang-Ki Min, Jae-Hoon Lee and Brian G M Durie. Pomalidomide Plus Dexamethasone (Pd) in the Treatment of Asian Patients with Relapsed/Refractory Myeloma (RRMM) Who Are Previously Treated with Bortezomib and Refractory to Lenalidomide – Interim Analysis of a Trial By the Asian Myeloma Network (AMN). ASH 2016 [Abstract 2130] (Invited poster presentation).
113. Sathish Kumar Gopalakrishnan, Shin-Yeu Ong, Seok Jin Kim, Hae Su Kim, MD, Ji Yun Lee, Sung Hee Lim, Yunxin Chen, Sanjay De Mel, Melissa G. Ooi, Shilpa Surendran, Adeline Lin, Daryl Tan, Brian G M Durie, Wee Joo Chng and Kihyun Kim. Bortezomib Based Induction Is Superior to Thalidomide Based Induction in Reducing Early Relapses Following Upfront HDM: an Analysis By the Asian Myeloma Working Group. ASH 2016 [Abstract 4650] (Invited poster presentation).
114. Cinnie Yentia Soekajo, Adeline Lin, Michelle Poon, Liang Piu Koh, Lip Kun Tan, Melissa G. Ooi and Wee Joo Chng. Cytogenetic Abnormalities and Treatment with New Drugs on Clinical Trials Are Important Prognostic Markers for Myeloma in the Era of ISS and FISH Analysis. ASH 2016 [Abstract 4498] (Invited poster presentation)
115. Pak Ling Lui, Rakshya Pandey, Jonathan Tian En Koh, Eng Soo Yap, Amartya Mukhopadhyay, and Wee Joo Chng. Outcome and Prognostic Factors of Patients with Hematological Malignancies Admitted to an Intensive Care Unit. ASH 2016 [Abstract 4796] (Invited poster presentation)

### **CLINICAL TRIALS**

1. Phase II trial of cdk inhibitor SCH 727965 in Multiple Myeloma (Role – PI; Initiated 2009; Recruitment closed, on follow-up, recruitment 5)
2. A Randomized, Open-label, Phase 2 Study of CNTO 328(Anti-IL-6 Monoclonal Antibody) and Velcade-Melphalan-Prednisone for the Treatment of Previously Untreated Multiple Myeloma (Role – PI; Initiated 2009; Recruitment closed, on follow-up, recruitment 2)
3. B1931008: An Open-Label, Randomized, Phase 3 Study Of Inotuzumab Ozogamicin Administered In Combination With Rituximab Compared To Defined Investigator's Choice Therapy In Subjects With Relapsed Or Refractory Cd22-Positive Aggressive Non-Hodgkin Lymphoma Who Are Not Candidates For Intensive High-Dose Chemotherapy. (Role – PI; Initiated 2009; Recruitment closed, recruited 2)
4. Rapid Rituximab infusion over 90-minute among non-Hodgkin Lymphoma (Role – PI, Initiated 2011; Recruitment closed, recruited 10)
5. A Phase 1 Dose Escalation and Pharmacokinetic Study of Alisertib (MLN8237), an Aurora A Kinase Inhibitor, in Adult East Asian Patients with Advanced Solid Tumors or Lymphomas (Role – PI, Initiated 2011; Recruitment closed, recruited 6)
6. Protocol PX-171-011: A Randomized, Open-label, Phase 3 Study of Carfilzomib vs Best Supportive Care in Subjects with Relapsed and Refractory Multiple Myeloma (Role PI; Initiated 2012; Recruitment closed, only open for 1 month, 0 recruitment)
7. Phase I/II dose-escalation study of oral administration of the Pan-Histone Deacetylase (HDAC) Inhibitor S 78454 in Hodgkin's Disease, non-Hodgkin Lymphoma and Chronic Lymphocytic Leukaemia (Role – PI; Initiated 2012; Recruitment closed, 0 recruitment)
8. A Phase 1 Pharmacokinetic Study of Oral MLN9708 Plus Lenalidomide and Dexamethasone in Adult Asian Patients With Relapsed and/or Refractory Multiple Myeloma (Role – PI; Initiated 2012; Active, recruitment 10)
9. A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Disease in Subjects with Newly Diagnosed Multiple Myeloma (Role – PI; Initiated 2012; Active, recruitment 10)
10. A randomized, open-label, phase 3 study of carfilzomib plus dexamethasone vs. bortezomib plus dexamethasone in patients with relapsed multiple myeloma. (Role – PI; Initiated 2012; Active, recruitment 15)
11. A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients with Relapsed and/or Refractory Multiple Myeloma (Role – PI; Active; Recruitment 5)



12. A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone versus Bortezomib, Melphalan, and Prednisone in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma (Role – PI; closed)
13. Phase 2 Trial of Single-agent Ibrutinib (PCI-32765) in Relapsed or Refractory Follicular Lymphoma (Role – PI; closed)
14. A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant (Role – PI; Active)

### **INVITED TALKS**

1. Haematology Seminar For Family Physicians: Management of Anticoagulation Therapy and Related Issues. 28 October 2001, Tan Tock Seng Hospital
2. Sysmax Scientific Seminar. Thrombophilia in Pregnancy. 6 Oct 2002, Raffles Hotel, Singapore
3. 9<sup>th</sup> ACMLT. Laboratory Investigation and diagnosis of von Willebrand's Disease. 18-22 Nov 2002, Singapore Polytechnics, Singapore.
4. NUH Grand Round. Red Cell Transfusion – Time for Self-regulation. 16 April 2004, NUH
5. Haematological Malignancies Forum: The genomic and molecular dissection of hyperdiploid myeloma. 20 Sept 2006, Mayo Clinic Rochester, MN, USA
6. NUH Research Grand Round. Understanding Cancer Genomics – The Key to Personalised Cancer Treatment. 30 Nov 2006. NUH.
7. Singapore Society of Haematology Annual Scientific Meeting. Multiple myeloma genomics – the past, present and future. April 2008, TTSH
8. Diagnostics Asia 2008. Personalized Medicine in Cancer – More Reality than Fiction. 27 May 2008, Meritus Mandarin, Singapore
9. American Society of Clinical Oncology 2008. Paper discussed gene expression profiles defining genetic subtypes, coupled with signatures of tumor biology and chemotherapy sensitivity provide a novel therapeutic approach to multiple myeloma. Theme: Individualized Care in Myeloma. 2 June 2008, McCormick Place Conference Center Chicago, USA
10. College of Physicians, Singapore 5<sup>th</sup> Annual Scientific Meeting. Modern Management of Multiple Myeloma. 6 July 2008, TTSH.
11. Laboratory Management 2008. The use of 'omics' applications towards personalized medicine. 11 July 2008, NUH.
12. 12<sup>th</sup> Asean Conference of Clinical Laboratory Scientists. The use of genomics towards personalized medicine 24 Aug 2008, Brunei.
13. Genomics as platform for personalized medicine in myeloma. NHG ASM 8 November 2008, Singapore
14. Using Genomics to understand biology of multiple myeloma. Immunology Program 11 November 2008, Singapore
15. ASH 2008 Update on Myeloma. 5<sup>th</sup> MSH and SSH Post ASH Scientific Meeting. 9-11 January 2009, Penang, Malaysia.
16. The Cancer Institute Oncology Grand Round. Moving beyond conventional management of multiple myeloma. 18 February 2009, NUH, Singapore
17. Celgene Asia Pacific Expert Meeting. Molecular Pathways in Multiple Myeloma. 14 March 2009, Taipei, Taiwan
18. Asia Oncology Summit. Multiple Myeloma: From genetics to therapeutics. 4 April 2009, Suntec Convention Center, Singapore.
19. Asia-Pacific Cytogenetic User Summit 2009. Understanding Clinical and Biological Implications of Genomic Instability in Multiple Myeloma Using aCGH. 7 May 2009; St Regis, Singapore
20. BIT 2<sup>nd</sup> Annual World Cancer Congress 2009. Multiple Myeloma: From genetics to therapeutics. 23 June 2009, International Conventional Center, Beijing, China
21. ISHTM and MHG Scientific Conference on "What's New In Myeloma", 12 Sept 2009, Hotel ITC Grand Central, Parel, Mumbai, India
22. Philippine Society of Haematology and Blood Transfusion 39<sup>th</sup> Convention. "New Treatment Paradigms in Myelodysplastic Syndrome, 15 Sept 2009, Edsa Shangri-La Hotel, Manila, Philippines
23. NHG Annual Scientific Meeting. Haematology-Oncology Track: Genetics of Natural Killer T cell Lymphoma. Suntec City Convention Center, Singapore
24. Leukaemias, Myeloma and other Haematological cancers: What every doctor should know in this day and age. Modern Management of Myeloma. 7 Nov 2009, Grand Copthorne Waterfront Hotel, Singapore
25. 1<sup>st</sup> BTG Haematologic Malignancy Conference. "Clinical relevance of genetic abnormalities in multiple myeloma. 6-7 Feb 2010, Shangri-la Hotel, Singapore
26. NUHS-ASTAR Stem Cell Symposium. "Cancer Stem Cells – Controversies and Opportunities". 26 March 2010, Singapore Polytechnic, Singapore
27. SSH ASM 2010. Potential Uses of Microarrays in Haematological Malignancies. 4 April 2010, TTSH Theatre Singapore.

28. Johnson and Johnson Asia-Pacific Multiple Myeloma Meeting 2010. Molecular Determinant of Velcade Respose. 15 May 2010, Intercontinental Grand Stanford Hotel, Hong Kong.
29. World Diagnostics Asia Conference 2010. Personalized Medicine in Cancer. 17 May 2010, Furama Riverside Hotel, Singapore
30. MM/MDS mini Summit 2010. Molecular Defects in MM. 3 July 2010, G Hotel, Penang, Malaysia.
31. Advance Medicine Course 2010. Are all monoclonal proteins from Myeloma. 24 July, Tan Tock Seng Hospital, Singapore
32. Models of Physiology and Disease. Multiple Myeloma: From Genetics to Therapeutics. 3 August, Center of Life Sciences Building, National University of Singapore, Singapore.
33. The First International Symposium on Myeloma and Lymphoma (ISML). Update on management of AL Amyloidosis. 25 Sept 2010, Shanghai, China.
34. Haematology Workshop. Targeting EZH2 in Acute Myeloid Leukemia. 28 Sept 2010, NUHS Auditorium, Singapore.
35. Frontiers in Cancer Science. Role of PRL3 in Haematologic Malignancies. Nov 2010, NUHS Auditorium, Singapore
36. 2<sup>nd</sup> Asian Lymphoma Forum and 9<sup>th</sup> Korean Society of Hematology Lymphoma Working Party Symposium. Identification of Novel Therapeutic Targets in NK-T Cell lymphoma through Genomics Approach. 27 Nov 2010, Asan Medical Center Auditorium, Seoul, South Korea.
37. Abbott Molecular Diagnostics in Haematology Meeting. Current and Future use of FISH and genomics in Multiple Myeloma. 17 Mar 2011, Inter-continental Hotel, Singapore
38. 2<sup>nd</sup> International Haematologic Malignancies Meeting "Bridging the Gap". Emerging Therapeutics in Myeloma. 19 March 2011, Shangri-La Hotel, Singapore
39. Malaysian Society of Haematology Meeting. State of the Art Management of Myeloma. 30 Apr 2011, Kuching, Sarawak, Malaysia
40. Malaysian Society of Haematology Meeting. **Plenary Lecture:** Advances in cancer genetics and genomics. 1 May 2011, Kuching, Sarawak, Malaysia.
41. Hong Kong Society of Myeloma Annual Scientific Meeting 2011. **Keynote Speaker:** The implication of gene expression profiling in myeloma regarding pathogenesis and therapy. 10 Sept 2011. Hong Kong
42. Turning Science Into Care 4<sup>th</sup> Abbott Diagnostics Asia Pacific and Japan Scientific Symposium. **Plenary Lecture:** Use of Companion Diagnostics to Achieve Truly Personalized Medicine. 28 Oct 2011. Grand Hyatt Hotel, Bangkok, Thailand.
43. HAA-ISHAPD 2011. Current Knowledge of the Molecular Pathogenesis of Multiple Myeloma. 30 Oct 2011. Sydney Convention and Exhibition Center, Sydney, Australia.
44. NUS-Baden-Wurttemberg 4<sup>th</sup> Joint Scientific Conference in Life Sciences. Role of PRL-3 in Leukemia. 24 Nov 2011. Freiburg, Germany.
45. NUS-Kyushu 10<sup>th</sup> Global-COE International Symposium and 7<sup>th</sup> Young Investigator Forum. System Biology Approach to Dissect PRL-3 Function in AML. 22 Dec 2011. CeLs Auditorium @ National University of Singapore, Singapore.
46. BTG 2012: The Third International Hematologic Malignancies Conference. Gene Expression Profiling in Multiple Myeloma. 25 Feb 2012, JW Marriot, Hong Kong.
47. AOS 2012. Therapeutic implications of molecular changes in multiple myeloma. 14 Apr 2012, Suntec Convention Center, Singapore.
48. 2<sup>nd</sup> International Symposium on Myeloma and Lymphoma. Myeloma FISH and Chips. 12 May 2012, Shanghai, China.
49. SingHealth Duke-NUS Scientific Congress 2012. Translational Genomics in Multiple Myeloma. 3 August 2012, Raffles City Convention Center, Singapore.
50. The Philippine Society of Hematology and Blood Transfusion 42<sup>nd</sup> Annual Convention. Updates in the Management of Multiple Myeloma. 2 September 2012, Crowne Plaza Manila Galleria, Manila, Philippines.
51. 1<sup>st</sup> Singapore Pathology Conference in Conjunction with 3<sup>rd</sup> Asia Pacific Symposium on Advanced Molecular Technologies. The Current Application of FISH in Multiple Myeloma. 20 October 2012, Singapore
52. 53<sup>rd</sup> Fall Meeting of the Korean Society of Hematology. miRNA deregulation in Natural Killer/T-cell lymphoma. 3 Nov 2012, Gyeongju, Korea.
53. 4<sup>th</sup> International Hematologic Malignancies Conference. Molecular Markers in NKTL. 22 Feb 2013, Hong Kong
54. 4<sup>th</sup> International Hematologic Malignancies Conference. Risk Stratification in Multiple Myeloma. 22 Feb 2013, Hong Kong
55. 14<sup>th</sup> International Myeloma Workshop. Functional Oncogenomics: A Tool for Identification and Validation of Targeted Therapies in Multiple Myeloma. 5 May 2013, Kyoto, Japan
56. 14<sup>th</sup> International Myeloma Workshop. Myeloma in Asia: Current State of Myeloma Treatment and Research in Singapore. 5 May 2013, Kyoto, Japan
57. 23<sup>rd</sup> Singapore Pharmacy Congress, pre-congress workshop. Multiple Myeloma – Updates and advances. 16 August 2013, Singapore.
58. 1<sup>st</sup> Union Summit Forum on Lymphoma and Myeloma. Risk Stratification and Risk-Adopted Treatment for multiple myeloma. 18 Oct 2013. Tianjin, China
59. Asia Pacific Multiple Myeloma Roundtable. Is MRD the new goal? 27 Oct 2013. Shanghai, China.

60. Frontiers in Cancer Science. EZH2 in haematologic malignancies: Friends or Foes? 6 Nov 2013, Singapore
61. 2013 Samsung Medical Center Amyloidosis Symposium. Genetics of AL Amyloidosis. 7 Nov 2013, Seoul, South Korea.
62. 2013 Fall Conference of the Korean Association of Immunologists. New Insights into Pathogenesis of Natural Killer / T-Cell lymphoma. 8 Nov 2013, Seoul, South Korea
63. 2014 Malaysian Society of Haematology Annual Meeting. Update on Treatment of Transplant Ineligible Patients with Multiple Myeloma. 5 April 2014, Kuala Lumpur, Malaysia
64. Asian Oncology Summit 2014. Epigenetics in lymphoid Malignancies. 12 April 2014, Kuala Lumpur, Malaysia
65. 11<sup>th</sup> International Conference of the Asian Clinical Oncology Society. Impact of Molecular Alterations on Myeloma Treatment. 4 May 2014, Taipei, Taiwan
66. 7<sup>th</sup> International Singapore Symposium of Immunology. Therapeutic Challenges in Haematologic Malignancies. 7 June 2014, Singapore, Singapore
67. 9<sup>th</sup> Asian Epigenomics Meeting. EZH2 in Haematologic Malignancies: Friends or Foe. 26 Aug 2014, Singapore, Singapore.
68. 3<sup>rd</sup> ASEAN Federation of Haematology Congress. Genomics in Multiple Myeloma. 25 Oct 2014, Bangkok, Thailand.
69. Asia Pacific B Cell Malignancies Meeting. Diagnosis of MM. 22 Nov 2014, Seoul, Korea.
70. 56<sup>th</sup> Spring Meeting of the Korean Society of Hematology. Upfront treatment of Transplant Eligible Newly Diagnosed Multiple Myeloma. 30 May 2015, Seoul, Korea
71. 77<sup>th</sup> Japanese Society of Haematology Annual Meeting. Asian Discussion Panel: Clinical Utility of Genomics in Multiple Myeloma. 18 Oct 2015, Kanazawa, Japan
72. Asia Pacific B cell Malignancies Meeting. Genetic and Epigenetic Abnormalities in B cell malignancies. 24-25 Oct 2015, Hong Kong.
73. 2015 International Scientific Meeting on Haematology, Oncology, Thrombosis and Transplantation in Indonesia. Current Management of MM from Induction Therapy to Bone Marrow Transplant Consolidation and Maintenance Therapy: Outcome and Safety. 13-15 November 2015 Jarkarta, Indonesia
74. 7<sup>th</sup> Asia Pacific International Congress of Anatomists. Phosphatase PRL-3 induces Stem Cell-Like Properties and Promotes Leukemogenesis in AML. 17-20 March 2016, Singapore
75. Medlab Asia Pacific 2016. Role of Immunotherapy for the treatment of Multiple Myeloma. 22-24 March 2016, Singapore
76. 2<sup>nd</sup> Bi-National Cancer Symposium. Non-canonical Role of EZH2 in Cancers. 31 April 2016, Singapore.
77. 13<sup>th</sup> Malaysian Society of Haematology Annual Scientific Meeting. Management of Multiple Myeloma in the Molecular Era. 14 Apr 2016, Kuala Lumpur, Malaysia
78. 36<sup>th</sup> World Congress of International Society of Hematology. Integrating NGS approaches into patient care: How I manage high-risk disease at presentation in a transplant eligible patient. 20 Apr 2016, Glasgow, United Kingdom.
79. Gordon Research Conference on Personalised Medicine. Personalised Medicine in Multiple Myeloma. 10 Jul 2016, HKUST, Hong Kong.
80. National B-cell Malignancies Expert Series. Evolving Treatment Concepts with Novel Agents for Long-term disease control in NDMM and RRMM. 7 Aug 2016, Kuala Lumpur, Malaysia
81. National B-cell Malignancies Expert Series. Re-assessing the current endpoints and MRD in myeloma. 7 Aug 2016, Kuala Lumpur, Malaysia
82. 2<sup>nd</sup> RNA Symposium. Abnormalities in RNA Editing in Myeloma. 8 September 2016, NUS, Singapore
83. 1<sup>st</sup> Australian Myeloma Workshop. Genetic Events in Multiple Myeloma. 10 September 2016, Yarra Valley, Melbourne, Victoria, Australia
84. 1<sup>st</sup> Australian Myeloma Workshop. Insight from Genomic Studies in Myeloma. 10 September 2016, Yarra Valley, Melbourne, Victoria, Australia
85. 21<sup>st</sup> Asia-Pacific Bone Marrow Transplant Meeting. Myeloma Debate: Role of Stem Cell Transplantation in the Era of Novel Agents. 28-30 October 2016, Singapore.
86. 21<sup>st</sup> Asia-Pacific Bone Marrow Transplant Meeting. Role of Post-transplant Consolidation and Maintenance in Multiple Myeloma. 28-30 October 2016, Singapore.
87. 57<sup>th</sup> Autumn Meeting of the Korean Society of Hematology. Emerging Roles of Exosomes in Leukemogenesis. 10 Nov 2016, Daejeon, Korea
88. NUS-Keio Joint Scientific Symposium: Frontiers of Translational Medicine from Cradle to Aging. Immunotherapy for Cancer – Advances and Challenges. 10 Jan 2017, NUS, Singapore

## **RESEARCH GRANTS**

1. Causes of prolonged APTT with normal PT in patients from general hospital. (PI – NHG grant 2002 - \$29,000 for 1 year)
2. Haematological malignancy database (PI – NHG Grant 2002 - \$50,000 over 2 years)

3. Thalidomide and cyclosporin in the management of MDS (collaborator, NHG grant 2002 - \$75,672 over 2 years)
4. Influence of ABO blood group on Von Willebrand Antigen levels, collagen binding and ristocetin co-factor assays in normal Chinese blood donors (NMRC R2003/009 - \$16,800)
5. Study of COX-2 expression in malignant plasma cells from serial patient samples by flow cytometry with correlation to known prognostic factors in myeloma (PI – NHG Grant 2003/NHG-STP/03001) - \$28,200 over 2 years)
6. Development of comprehensive cancer gene repository for multiple myeloma (PI – SCS Grant 2007 - \$1,387,000 for 3 years)
7. Using Genomics to understand drug resistance and established drug connectivity in multiple myeloma (PI – NMRC / NUS Start-up 2008 - \$230,000 for 2 years)
8. Using unbiased forward genetic screen and comparative genomics in mice to model progression and transformation of multiple myeloma (PI – NMRC/CSA/001/2008 - \$675,000 for 3 years)
9. Investigating status of tumorigenic barriers in monoclonal gammopathy of undetermined significance and multiple myeloma (PI – NMRC/EDG/0025/2008 - \$200,000 for 2 years)
10. Immunotherapy of Multiple Myeloma by CD137. (Collaborator – NMRC/1175/2008 - \$585,000 for 3 years)
11. MicroRNA profiling in Childhood Acute Lymphoblastic Leukemia (PI – NMRC EDG08nov022 - \$199,665 for 2 years)
12. Phenotypic and molecular studies of clonogenic myeloma cells (PI – AcRF Tier 2 MOE2009-T2-2-073 - \$905,610 for 3 years)
13. Investigating the biologic role and clinical relevance of RUNX genes in NK/T-cell lymphoma. (Collaborator – FRC \$179,997 for 3 years)
14. Identifying Potential Biomarkers Functionally linked to t(4;14) Multiple Myeloma Using Plasma Membrane Proteomics (PI – NMRC EDG \$184,400 for 2 years)
15. XIAP in Acute Myeloid Leukemia (PI – Roche 2011 \$192,000 for 1 year)
16. Clinical Relevance of PRL3, p53 and MDM2 Expression in AML. (PI – NUHS Clinician Research Grant 2011 \$100,000 over 2 years)
17. Genomic-based diagnosis, Classification & Targeted Treatment of Multiple Myeloma (PI – NMRC CSA 2012 \$1,750,000 for 5 years)
18. Project to investigate the efficacy of thymoquinone as an anti-multiple myeloma agent that can overcome chemoresistance through the suppression of STAT3 signalling cascade. (Clinical PI – NUHS Bench-to-Bedside 2012 \$100,000 over 2 years)
19. EZH2 Deregulation in NKTL. (PI – NMRC CS-IRG (NMRC/CIRG/1343/2012) Nov 2012 \$797,500 over 3 years))
20. Investigating the oncogenic role of a small tyrosine phosphatase, PRL-3 in acute myeloid leukemia and its potential therapeutic intervention. (PI – NMRC CS-IRG (CIRG12nov048) May 2013 SGD\$ 1,281,718.00 for 3 years)
21. Development of bone-marrow-on-a-chip for in vitro drug testing in haematologic malignancies. (PI – NCIS Pilot Project Grant 2014, \$50,000 for 18 mths)
22. Preclinical and clinical development of celastrol for the treatment of multiple myeloma. (Clinical PI – NUHS Bench to Bedside 2014, \$100,000 for 2 years)
23. Serum miRNA as Biomarker for patients with myeloid malignancies treated with hypomethylating agents. (Clinical PI – NUHS Bench to Bedside 2014, \$100,000 for 2 years)
24. Utility of PET-MRI in Multiple Myeloma. (PI – NCIS Pilot Project Grant 2014, \$100,000 over 2 years)
25. Development of Immunotherapy Targeting Cancer Stem Cell Biomarker Tim-3 for Acute Myeloid Leukemia (Clinical PI – NMRC BnB Grant, \$1,000,000 over 3 years)
26. Targeting PHF8, histone demethylase in Diffuse Large B-cell Lymphoma (PI – Yong Siew Yoon Research Grant, \$200,000 over 2 years)

### **PATENTS**

US Provisional Patent Application No. 62/157,348

Invention: Improved Drug Combinations For Drug-Resistant and Drug-Sensitive Multiple Myeloma Developed Using Feedback System Control Platform

### **RESEARCH INTEREST**

Multiple Myeloma, liquid tumour biology and therapeutics

### **LEADERSHIP TRAINING**

- 1) NUHS Leadership Milestone Program (2012)
- 2) MOH Healthcare Family Emerging Leadership Program (2013)
- 3) MOHH Strategic Leadership Program (2015)
- 4) Managing Healthcare Delivery (2016-17) – Harvard Business School Executive Program

